Research activity information

• Sep. 2025 Kinki Branch of the Japan College of Rheumatology, Excellent abstract award, アバタセプト投与中に皮膚血管炎を発症した関節リウマチの一例

  Sho Sendo


• Sep. 2025 Asia-Pacific League of Associations for Rheumatology (APLAR), Congress Travel Grant 2025, Upregulated Neddylation is a Potential Target for Arthritis in SKG mice

  Sho Sendo

  共同研究・競争的資金等の業績IDIRI


• Jul. 2024 The Japanese Society of Inflammation and Regeneration, Excellent abstract award an 45th annual meeting of the Japanese Society of Inflammation and Regeneration, Controlling Dysregulated Neddylation in RA FLS as a novel Therapeutic Target of Rheumatoid Arthritis

  Sho Sendo


• Dec. 2018 先進医薬研究振興財団, 平成30年度 先進医薬研究振興財団 血液医学分野海外留学助成, 国内の医療施設またはそれに準ずる研究機関に所属する医師または研究者で大学およびその付属機関においては教授、研究所および研究施設においては部門長の推薦を受けた者

  Sendou Shou

  Publisher


• Oct. 2017 一般社団法人日本リウマチ学会, 第4回ベーシックリサーチカンファレンス最優秀演題賞, 発表者

  千藤荘

  Japan society


• Oct. 2017 International Cytokine and Interferon Society, Kishimoto Travel Award, Presenter of the 5th Annual Meeting of the International Cytokine and Interferon Society

  ShoSendo

  International society


• Jul. 2017 日本炎症・再生医学会, 第38回日本炎症・再生医学会優秀演題賞, 発表者

  千藤荘

  Japan society


• May 2017 日本リウマチ財団, Japanese Rheumatism Foundation International Conference Travel Award, EULAR 2017

  Sho Sendo

• Recovery trajectories of TAFRO syndrome: a single-center case series highlighting prolonged thrombocytopenia and anasarca.

  Chiharu Miyamoto, Yo Ueda, Hirotaka Yamada, Naoe Jimbo, Takaichi Okano, Keisuke Nishimura, Sho Sendo, Tomoo Itoh, Jun Saegusa

  TAFRO syndrome is a rare systemic inflammatory disorder characterized by thrombocytopenia, anasarca, fever or inflammation, reticulin fibrosis or renal dysfunction, and organomegaly. Despite increasing recognition, its natural history, particularly the timeline of organ-specific recovery, remains poorly understood. We retrospectively analyzed seven patients, encompassing nine treatment courses, diagnosed with TAFRO syndrome at our institution. Time to recovery was assessed across four clinical domains-renal dysfunction, systemic inflammation, anasarca, and thrombocytopenia-using predefined objective criteria. The median time to recovery was 7.0 days for renal dysfunction, 21.0 days for systemic inflammation, 24.0 days for anasarca, and 46.0 days for thrombocytopenia. Recovery of thrombocytopenia and anasarca tended to be delayed compared with that of renal dysfunction and systemic inflammation, with thrombocytopenia showing the longest median time to recovery. These findings indicate substantial heterogeneity in organ-specific recovery trajectories in TAFRO syndrome, with hematologic and fluid-related manifestations resolving more slowly than inflammatory or renal abnormalities. Recognition of domain-specific recovery timelines may aid interpretation of treatment responses and support more balanced, individualized management strategies.

  Mar. 2026, Immunological medicine, 1 - 11, English, International magazine

  Scientific journal


• Clostridioides difficile検査におけるNAAT導入効果の検討

  楠木 まり, 田村 直暉, 大沼 健一郎, 大路 剛, 千藤 荘, 宮良 高維

  (一社)日本感染症学会, Mar. 2026, 感染症学雑誌, 100(2) (2), 242 - 242, Japanese


• Clinical performance of three anti-dsDNA antibody immunoassays in systemic lupus erythematosus.

  Kenichi Uto, Natsuki Yoshida, Takaichi Okano, Mai Yamashita, Nobuhide Hayashi, Takamitsu Imanishi, Yoshihiko Yano, Jun Saegusa, Sho Sendo

  OBJECTIVES: To evaluate the clinical performance of three commercially available anti-dsDNA antibody immunoassays in Japan. METHODS: We compared the reactivity and diagnostic accuracy of three commercially available anti-dsDNA antibody immunoassays (radioimmunoassay [RIA], chemiluminescence enzyme immunoassay [CLEIA], and fluorescence enzyme immunoassay [FEIA]). We evaluated how well the three anti-dsDNA antibody immunoassays reflected disease activity and individual organ involvement in systemic lupus erythematosus (SLE). RESULTS: Three anti-dsDNA antibody immunoassays demonstrated moderate to substantial correlation and concordance, while some patients exhibited different reactivity because of assay principles and detection systems. The diagnostic accuracies of the three immunoassays were comparable based on the receiver operating characteristic analyses and optimal cutoff values. Among the three anti-dsDNA antibody immunoassays, a fully automated CLEIA-specific detection system demonstrated high sensitivity that reflects disease activity. The combined results of the titers and positivity rates of the three anti-dsDNA antibody immunoassays showed that nephritis was significantly associated with CLEIA and arthritis with RIA, and weak or no associations with other organ involvement were observed. CONCLUSIONS: We confirmed that the clinical performances of the three dsDNA immunoassays are comparable. Our findings suggest that selecting an optimal anti-dsDNA immunoassay will be useful for clinical decision-making in SLE.

  Feb. 2026, Modern rheumatology, English, International magazine

  Scientific journal


• Mode of action-specific and cause-specific retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in anti-SS-A antibody-positive rheumatoid arthritis: The ANSWER cohort study.

  Kazuma Nishisaka, Takaichi Okano, Takumi Imai, Masanori Tsubosaka, Tomoyuki Kamenaga, Naoki Nakano, Shinya Hayashi, Wataru Yamamoto, Akira Onishi, Kosaku Murakami, Kohei Tsujimoto, Masao Katsushima, Ayaka Yoshikawa, Takuya Kotani, Hideki Amuro, Yonsu Son, Tetsu Itami, Yuji Nozaki, Yoko Nose, Mai Yamashita, Iku Shirasugi, Hirotaka Yamada, Keisuke Nishimura, Yo Ueda, Sho Sendo, Motomu Hashimoto, Ryosuke Kuroda, Jun Saegusa

  Anti-SS-A (Ro) antibody-positive rheumatoid arthritis (RA) constitutes a clinically important subgroup, but its impact on retention of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) across different modes of action (MOA) and reasons for discontinuation remains unclear. We conducted a multicenter retrospective analysis of the Japanese ANSWER cohort, including RA patients who started or switched b/tsDMARDs between 2011 and 2024 and had baseline anti-SS-A antibody testing. Among 1,452 patients (2,703 treatment courses), 255 patients (17.6%) were anti-SS-A antibody positive (507 courses, 18.8%). Propensity score matching balanced baseline characteristics, and drug retention was evaluated using Kaplan-Meier and competing risk analyses. Overall discontinuation was analyzed using Cox proportional hazards models, and Fine-Gray subdistribution hazards models were used for discontinuation by reason and for adverse event-related discontinuation stratified by MOA. After matching, 507 treatment courses from 255 anti-SS-A antibody-positive patients and 1,014 courses from 628 antibody-negative patients were analyzed. Anti-SS-A antibody positivity was not associated with overall b/tsDMARD retention (hazard ratio [HR] 1.07, 95% confidence interval [CI] 0.91-1.26, p = 0.382). In MOA-stratified analyses, positivity showed a trend toward increased discontinuation with interleukin-6 (IL-6) receptor inhibitors and cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4-Ig). In competing-risk analyses, discontinuation due to adverse events was significantly more frequent in antibody-positive patients (subdistribution hazard ratio [sHR] 1.80, 95% CI 1.28-2.52; p = 0.000685). Among adverse event-related discontinuations, anti-SS-A antibody positivity was associated with higher risks with IL-6 receptor inhibitors (sHR 2.41, 95% CI 1.24-4.71; p = 0.0098) and tumor necrosis factor (TNF) inhibitors (sHR 2.04, 95% CI 1.22-3.40; p = 0.0066), but not with CTLA4-Ig or Janus kinase (JAK) inhibitors. These findings suggest that treatment tolerability, rather than overall efficacy, may be a key determinant of b/tsDMARD survival in anti-SS-A antibody-positive RA and that MOA- and cause-specific profiles should be considered when selecting therapies in this subgroup.

  2026, PloS one, 21(3) (3), e0344747, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• A Woman in Her 60s Referred for Evaluation of Thrombocytopenia

  千藤荘, 志谷映璃, 宮下竜伊, 松本剛, 常川勝彦

  (一社)日本臨床検査医学会, Jan. 2026, 日本臨床検査医学会誌, 74(1) (1), 128 - 133, Japanese


• Effect of treat-to-target strategies on maternal and neonatal outcomes of rheumatoid arthritis: a multicentre real-world ANSWER cohort study.

  Yuri Hiramatsu, Takuya Kotani, Eri Nakamura, Ayaka Yoshikawa, Motomu Hashimoto, Akira Onishi, Kouichi Murata, Natsuki Yamamoto, Kosaku Murakami, Toru Hirano, Yuichi Maeda, Kosuke Ebina, Sho Sendo, Yonsu Son, Hideki Amuro, Ryota Hara, Masaki Katayama, Wataru Yamamoto, Tohru Takeuchi

  OBJECTIVES: We evaluated real-world disease activity, treatment patterns, and pregnancy outcomes in women with rheumatoid arthritis (RA) utilizing a multicentre Japanese cohort. Feasibility and impact of a treat-to-target (T2T) approach during pregnancy were also examined. METHODS: A retrospective observational study analysed 118 pregnancies in patients with RA from the multicentre ANSWER cohort (2013-2023) across eight Japanese academic institutions. Clinical characteristics, treatment regimens, and RA Disease Activity Scores of 28 joints, based on C-reactive protein (DAS28-CRP), were assessed at preconception, during each trimester, and postpartum. Pregnancy and neonatal outcomes were analysed. RESULTS: Of 118 pregnancies, 92.8% achieved full-term deliveries (median birthweight: 2949 g). Remission or low disease activity was maintained in ∼85% of patients throughout pregnancy, with increased postpartum disease activity. Patients who continued biologic disease-modifying antirheumatic drugs (bDMARDs) during pregnancy (n = 35) exhibited significantly lower DAS28-CRP scores during the second and third trimesters compared with those who discontinued (n = 24) (p = 0.007 and p = 0.0002, respectively). Etanercept or certolizumab pegol use was associated with favourable disease control. Tocilizumab (n = 6) or abatacept (n = 2) was not associated with adverse maternal or neonatal outcomes. Glucocorticoid use was associated with increased disease activity. Salazosulfapyridine use correlated with increased birth weight (p = 0.003) and gestational age (p = 0.051). CONCLUSION: T2T management, including selective continuation of bDMARDs, was associated with favourable maternal disease control and reassuring pregnancy outcomes. Although the absence of long-term follow-up is a limitation, these findings provide real-world evidence supporting this approach. Larger prospective studies are required to confirm maternal and neonatal safety beyond the early postpartum.

  Oct. 2025, Rheumatology (Oxford, England), 65(1) (1), English, International magazine

  Scientific journal


• Clinical Efficacy of JAK Inhibitors for Rheumatoid Arthritis Patients with Poor-Prognosis Factors: The ANSWER Cohort Study.

  Yuji Nozaki, Koichi Murata, Akira Onishi, Kohei Tsujimoto, Wataru Yamamoto, Hirotaka Yamada, Sho Sendo, Motomu Hashimoto, Tadashi Okano, Hideyuki Shiba, Yuri Hiramatsu, Yonsu Son, Naofumi Yoshida, Rika Fukuda, Yumi Morimoto, Kazuya Kishimoto, Tetsu Itami, Daisuke Tomita, Chisato Ashida, Toshihiko Shiga, Koji Kinoshita

  OBJECTIVES: We evaluated the efficacy of Janus kinase inhibitors (JAKi) compared with tumor necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA) patients with poor-prognosis factors (PPFs), including ACPA or RF positivity, Clinical Disease Activity Index (CDAI) ≥22, CRP ≥0.6 mg/dl, and HAQ-DI ≥0.5. We focused on treatment continuation, disease control, and glucocorticoid (GC) reduction. PATIENTS AND METHODS: We conducted a retrospective analysis of the ANSWER cohort, including 1,794 RA patients treated with a TNFi (n = 1,235) or JAKi (n = 559). Propensity score-matching was applied to reduce bias. We categorized the patients into those with 4PPFs or < 4 PPFs. Treatment persistence, CDAI changes, and GC tapering over 24 months were analyzed. RESULTS: JAKi treatment demonstrated greater CDAI reduction (JAKi vs TNFi median: -23.3 vs -19.9), particularly in ACPA-positive patients. In the 4PPFs patients, JAKi treatment led to a significantly higher low-disease-activity achievement rate compared with TNFi (68.8% vs 60.9%) at 24 months. JAKi treatment also enabled faster GC tapering, with 72.4% discontinuation compared with 50.3% in the TNFi group at 24 months. Among the 4PPFs patients, JAKi treatment facilitated a greater (but nonsignificant) reduction in GC dosage over time. The cumulative GC discontinuation rate remained consistently higher in the JAKi group, reaching 61.3% vs 48.4% in the TNFi group at 24 months. CONCLUSIONS: JAKi treatment provided sustained disease control (especially in high-risk RA patients) and promoted GC reduction. Although TNFi remains a standard option, JAKi treatment may be preferable in patients with 4PPFs. Further research should evaluate JAKi treatment's long-term safety and efficacy.

  Oct. 2025, Rheumatology (Oxford, England), 65(1) (1), English, International magazine

  Scientific journal


• 膠原病・リウマチ性疾患患者のプレコンセプションケア 最近の診療と治療の進歩

  千藤 荘

  (一社)兵庫県医師会, Sep. 2025, 兵庫県医師会医学雑誌, 68(1) (1), 10 - 12, Japanese


• 自動搬送ラインを活用した検体処理プロセスの安定性評価とバイオリソース提供における品質担保

  金 貞姫, 佐藤 伊都子, 勝亦 柚衣, 森本 耕平, 岡野 隆一, 中村 恵宣, 岡崎 葉子, 今西 孝充, 松岡 広, 千藤 荘

  (一社)日本医療検査科学会, Aug. 2025, 医療検査と自動化, 50(4) (4), 281 - 281, Japanese


• 病院併設型バイオバンクにおける全血残余検体の収集・提供体制の評価

  勝亦 柚衣, 金 貞姫, 佐藤 伊都子, 森本 耕平, 岡野 隆一, 中村 恵宣, 岡崎 葉子, 今西 孝充, 千藤 荘, 松岡 広

  (一社)日本医療検査科学会, Aug. 2025, 医療検査と自動化, 50(4) (4), 283 - 283, Japanese


• 自動搬送ラインを活用した検体処理プロセスの安定性評価とバイオリソース提供における品質担保

  金 貞姫, 佐藤 伊都子, 勝亦 柚衣, 森本 耕平, 岡野 隆一, 中村 恵宣, 岡崎 葉子, 今西 孝充, 松岡 広, 千藤 荘

  (一社)日本医療検査科学会, Aug. 2025, 医療検査と自動化, 50(4) (4), 281 - 281, Japanese


• 病院併設型バイオバンクにおける全血残余検体の収集・提供体制の評価

  勝亦 柚衣, 金 貞姫, 佐藤 伊都子, 森本 耕平, 岡野 隆一, 中村 恵宣, 岡崎 葉子, 今西 孝充, 千藤 荘, 松岡 広

  (一社)日本医療検査科学会, Aug. 2025, 医療検査と自動化, 50(4) (4), 283 - 283, Japanese


• Interaction between haploinsufficiency of PTPN2 and patient microbiome promotes autoimmune arthritis in mice.

  Sho Sendo, Allison J Vela, Myungja Ro, Deepan Thiruppathy, Elizabeth L Wilkinson, Zixuan Zhao, Wan-Chen Hsieh, Shen Yang, Roxana Coras, Anne-Sophie Bergot, Monica Guma, Anders Nguyen, David A McBride, Suzanne Devkota, Ranjeny Thomas, Nisarg J Shah, Mattias N D Svensson, Karsten Zengler, Stephanie M Stanford, Nunzio Bottini

  Gut dysbiosis is observed in patients with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), however, how it promotes disease in interaction with other environmental and genetic risk factors remains unclear. Here we assessed interactions between gut dysbiosis and RA/JIA-associated loss of function haplotypes of the RA/JIA-associated PTPN2 gene by inducing mannan-induced arthritis in germ-free PTPN2+/+ and PTPN2 haploinsufficient (PTPN2+/-) SKG mice reconstituted with fecal microbiota from six patients with seropositive RA. Mannan-induced arthritis and lymph node T cell immunophenotypes were identical in germ free PTPN2+/+ vs PTPN2+/- SKG mice. While no difference in arthritis severity was seen among PTPN2+/+ mice recipient of RA gut microbiota, two microbiomes (RA#02 and RA#86) enhanced arthritis in PTPN2+/- mice. The microbiome of RA patient microbiota recipient mice exclusively clustered by patient of origin and the RA#86 microbiome was found to carry a significant expansion of Prevotella genera, which is associated with RA dysbiosis. RA#86 microbiota-recipient PTPN2+/- mice selectively displayed increased joint GM-CSF expression and an expansion of CD4+RORγt+FoxP3- T cells in the joints, without evidence of increased intestinal inflammation, gut barrier leakage or expansion of P. copri in post-mannan fecal samples. Monocolonization with P. copri caused enhanced arthritis and CD4+RORγt+FoxP3- T cells expansion in PTPN2+/- vs PTPN2+/+ mice. Our data support current views about P. copri promotion of autoimmune arthritis and suggest that its pathogenicity can be amplified via interaction with a dysbiotic context and risk factors that enhance gut mucosa immune responses.

  Jul. 2025, Journal of autoimmunity, 156, 103452 - 103452, English, International magazine

  Scientific journal


• Fib4 indexは関節リウマチ患者においてMTX継続率を予想する

  岡野 隆一, 佐藤 伊都子, 中村 恵宣, 松岡 広, 千藤 荘, 三枝 淳

  (一社)日本臨床検査医学会, Jul. 2025, 日本臨床検査医学会誌, 73(補冊) (補冊), 206 - 206, Japanese


• Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study.

  Akira Onishi, Masao Tanaka, Takayuki Fujii, Koichi Murata, Kosaku Murakami, Motomu Hashimoto, Ryu Watanabe, Yuji Nozaki, Chisato Ashida, Wataru Yamamoto, Hirotaka Yamada, Sho Sendo, Kosuke Ebina, Hidehiko Makino, Yonsu Son, Yumiko Wada, Kenichiro Hata, Shuichi Matsuda, Akio Morinobu

  BACKGROUND: While targeting the interleukin-6 receptor (IL-6R) through the use of sarilumab (SAR) or tocilizumab (TCZ) has become a major therapeutic approach for rheumatoid arthritis (RA), direct comparisons between IL-6R inhibitors (IL-6Ris) for treating RA have not been conducted. We aimed to compare the effectiveness of subcutaneous sarilumab (SAR-SC), subcutaneous tocilizumab (TCZ-SC), and intravenous TCZ (TCZ-IV) against RA in a multicenter cohort study. METHODS: Within the target trial emulation framework, an incident new-user and active-comparator cohort design was used. The source population was the entire cohort of a multicenter prospective study (the ANSWER cohort study) in Japan from 2009 to 2023. We consecutively included patients with IL-6Ri-naïve RA who initiated treatment with SAR-SC 200 mg biweekly, TCZ-SC 162 mg biweekly, or TCZ-IV 8 mg/kg every 4 weeks as the approved starting dose and dosing interval at baseline. The primary outcome of interest was the change in the clinical disease activity index (CDAI) at 24 weeks. RESULTS: In total, 1001 IL-6Ri-naïve patients were included (SAR-SC 200 mg biweekly, 201 patients; TCZ-SC 162 mg biweekly, 546; TCZ-IV 8 mg/kg every 4 week, 254). The improvement in CDAI at 24 weeks (primary outcome) was statistically significantly greater in the SAR-SC group than in the TCZ-SC group (-2.53, 95% confidence interval (CI): -4.38 to -0.69, p = 0.007), but that in TCZ-IV was not significantly different from that in TCZ-SC (1.00, 95% CI: -0.68 to 2.69, p = 0.243). Similar results were noted regarding the changes in CDAI at weeks 4, 12, and 48. The retention rates at 48 weeks in SAR-SC and TCZ-IV did not significantly differ from that in TCZ-SC. CONCLUSIONS: SAR-SC 200 mg biweekly initiation was associated with a statistically significantly greater decrease in disease activity than TCZ-SC 162 mg biweekly in IL-6Ri-naïve patients with RA. In contrast, no statistically significant differences were identified between TCZ-IV 8 mg/kg every 4 week and TCZ-SC 162 mg biweekly. However, the effect size of our findings should necessitate careful consideration of the cost difference between TCZ-SC 162 mg biweekly including its biosimilars and SAR-SC 200 mg biweekly.

  Mar. 2025, Arthritis research & therapy, 27(1) (1), 52 - 52, English, International magazine

  Scientific journal


• Idiopathic multicentric Castleman disease-TAFRO after COVID-19: A case report.

  Tatsuro Shiina, Eriko Kashihara Yamamoto, Hirotaka Yamada, Sho Sendo, Maki Kanzawa, Jun Saegusa

  TAFRO syndrome, a rare disease characterised by thrombocytopaenia, anasarca, fever, reticulin fibrosis, and organomegaly, is thought to be caused by hypercytokinaemia. It is a heterogeneous clinical entity, and a recent comprehensive international definition defined TAFRO syndrome with lymph node histopathology consistent with idiopathic multicentric Castleman disease (iMCD) as iMCD-TAFRO. Herein, we present a rare case of iMCD-TAFRO following coronavirus disease 2019 (COVID-19) infection. A 62-year-old Japanese woman, initially diagnosed with COVID-19, developed a persistent fever and fluid retention, prompting the diagnosis of iMCD-TAFRO. Following the initiation of prednisolone and cyclosporine, her symptoms gradually resolved. Therefore, we discuss the potential pathophysiological link between COVID-19 and iMCD-TAFRO, emphasising the role of cytokine storms. This case report highlights the importance of recognising the spectrum of inflammatory states after COVID-19 and differentiating iMCD-TAFRO after COVID-19 from the COVID-19 cytokine storm syndrome.

  Jan. 2025, Modern rheumatology case reports, 9(1) (1), 174 - 178, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Zymosan-Treated SKG Mice: Assessing Effects of Systemic Inflammation on the Temporomandibular Joint.

  Kaito Uryu, Yasumasa Kakei, Sho Sendo, Ikuko Goto, Kengo Akashi, Keisuke Nishimum, Tatsuya Shirai, Junya Hirota, Daisuke Takeda, Manabu Shigeoka, Akira Kimoto, Takumi Hasegawa, Jun Saegusa, Masaya Akashi

  OBJECTIVES: The effects of systemic inflammation on the temporomandibular joint (TMJ) are poorly understood. This study aimed to establish a mouse model to study the effects of systemic inflammation on the TMJ. MATERIALS AND METHODS: SKG mice, a BALB/c strain with spontaneous onset of rheumatoid arthritis-like symptoms due to a spontaneous point mutation (W163C) in the gene encoding the SH2 domain of ZAP-70, were treated with zymosan (β-1,3-glucan). Synovitis, bone erosion, and cartilage damage in the TMJ were evaluated using established scores for animal models of inflammatory arthritis. Myeloperoxidase-positive areas and numbers of tartrate-resistant acid phosphatase (TRAP)-positive cells were compared between naive and zymosan-treated SKG mice. Correlations between TMJ inflammation scores and clinical scores for extremities were also assessed. RESULTS: There were significant differences in TMJ inflammation scores, including synovitis, bone erosion, and cartilage damage, between naive and high-dose zymosan-treated mice. There were significant differences in myeloperoxidase-positive areas and numbers of TRAP-positive cells between naive and zymosan-treated mice. There were significant correlations between TMJ inflammation scores and clinical scores for extremities. CONCLUSIONS: Systemic administration of zymosan efficiently induces TMJ inflammation in SKG mice. Zymosan-treated SKG mice offer a useful tool to investigate the effects of systemic inflammation on the TMJ.

  Dec. 2024, Oral diseases, 31(6) (6), 1831 - 1840, English, International magazine

  Scientific journal


• Musculoskeletal ultrasound findings in adult-onset Still's disease: A case series.

  Eriko Kashihara Yamamoto, Hirotaka Yamada, Sho Sendo, Haruka Yasuba, Keisuke Nishimura, Yo Ueda, Jun Saegusa

  Adult-onset Still's disease (AOSD) is a rare systemic inflammatory disorder of unknown etiology characterized by high spiking fever, salmon-like skin rash, arthritis, and elevated serum ferritin levels. Early detection of AOSD is remarkably difficult because of the lack of serologic biomarkers, nonspecific presentation, and rarity of the disease. Although arthralgia and arthritis are the most frequent symptoms and are correlated with health-related quality of life in patients with AOSD, the inflammatory changes associated with these symptoms have not been elucidated. We performed musculoskeletal ultrasound (MSKUS) in 11 patients between January 1, 2008 and July 31, 2023, seven of whom had abnormalities. MSKUS findings of those cases suggested that some patients with AOSD could present with tenosynovitis, tendonitis/peritendonitis, bursitis, and enthesitis along with synovitis. This case series demonstrate the diversity of inflammatory articular manifestations of AOSD identified by MSKUS.

  Dec. 2024, Joint bone spine, 91(6) (6), 105771 - 105771, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Laser Capture Microscopy RNA Sequencing for Topological Mapping of Synovial Pathology During Rheumatoid Arthritis.

  Benjamin Van Espen, E Barton Prideaux, Andrew R Wilson, Camilla R L Machado, Sho Sendo, James Parker, Grégory Seumois, Cristiano Sacchetti, Anna C Belongia, Narayanan B Perumal, Pandurangan Vijayanand, Matthew D Linnik, Robert J Benschop, Wei Wang, Nunzio Bottini, Gary S Firestein, Stephanie M Stanford

  OBJECTIVE: Rheumatoid arthritis (RA) is an autoimmune disease in which the joint lining or synovium becomes highly inflamed and majorly contributes to disease progression. Understanding pathogenic processes in RA synovium is critical for identifying therapeutic targets. We performed laser capture microscopy (LCM) followed by RNA sequencing (LCM-RNAseq) to study regional transcriptomes throughout RA synovium. METHODS: Synovial lining, sublining, and vessel samples were captured by LCM from seven patients with RA and seven patients with osteoarthritis (OA). RNAseq was performed on RNA extracted from captured tissue. Principal component analysis was performed on the sample set by disease state. Differential expression analysis was performed between disease states based on log2 fold change and q value parameters. Pathway analysis was performed using the Reactome Pathway Database on differentially expressed genes among disease states. Significantly enriched pathways in each synovial region were selected based on the false discovery rate. RESULTS: RA and OA transcriptomes were distinguishable by principal component analysis. Pairwise comparisons of synovial lining, sublining, and vessel samples between RA and OA revealed substantial differences in transcriptional patterns throughout the synovium. Hierarchical clustering of pathways based on significance revealed a pattern of association between biologic function and synovial topology. Analysis of pathways uniquely enriched in each region revealed distinct phenotypic abnormalities. As examples, RA lining samples were marked by anomalous immune cell signaling, RA sublining samples were marked by aberrant cell cycle, and RA vessel samples were marked by alterations in heme scavenging. CONCLUSION: LCM-RNAseq confirms reported transcriptional differences between the RA synovium and the OA synovium and provides evidence supporting a relationship between synovial topology and molecular anomalies in RA.

  Aug. 2024, Arthritis & rheumatology (Hoboken, N.J.), 76(8) (8), 1243 - 1251, English, International magazine

  Scientific journal


• Dysregulated NUB1 and Neddylation Enhances Rheumatoid Arthritis Fibroblast-Like Synoviocyte Inflammatory Responses.

  Sho Sendo, Camilla R L Machado, David L Boyle, Robert J Benschop, Narayanan B Perumal, Eunice Choi, Wei Wang, Gary S Firestein

  OBJECTIVE: Fibroblast-like synoviocytes (FLS) contribute to the pathogenesis of rheumatoid arthritis (RA), in part due to activation of the proinflammatory transcription factor NF-κB. Neddylation is modulated by the negative regulator of ubiquitin-like protein (NUB) 1. We determined whether NUB1 and neddylation are aberrant in the models with RA FLS, thereby contributing to their aggressive phenotype. METHODS: Models with RA or osteoarthritis (OA) FLS were obtained from arthroplasty synovia. Real-time quantitative polymerase chain reaction and Western blot analysis assessed gene and protein expression, respectively. NUB1 was overexpressed using an expression vector. NF-κB activation was assessed by stimulating FLS with interleukin (IL)-1β. Neddylation inhibitor (MLN4924) and proteasome inhibitor were used in migration and gene expression assays. MLN4924 was used in the model with K/BxN serum-transfer arthritis. RESULTS: Enhanced H3K27ac and H3K27me3 peaks were observed in the NUB1 promoter in the OA FLS compared with the RA FLS. NUB1 was constitutively expressed by FLS, but induction by IL-1β was significantly greater in the OA FLS. The ratio of neddylated cullin (CUL) 1 to nonneddylated CUL1 was lower in the OA FLS than the RA FLS. NUB1 overexpression decreased NF-κB nuclear translocation and IL-6 messenger RNA (mRNA) in IL-1β-stimulated the RA FLS. MLN4924 decreased CUL1 neddylation, NF-κB nuclear translocation, and IL-6 mRNA in IL-1β-stimulated the RA FLS. MLN4924 significantly decreased arthritis severity in the model with K/BxN serum-transfer arthritis. CONCLUSION: CUL1 neddylation and NUB1 induction is dysregulated in the models with RA, which increases FLS activation. Inhibition of neddylation is an effective therapy in an animal model of arthritis. These data suggest that the neddylation system contributes to the pathogenesis of RA and that regulation of neddylation could be a novel therapeutic approach.

  Aug. 2024, Arthritis & rheumatology (Hoboken, N.J.), 76(8) (8), 1252 - 1262, English, International magazine

  Scientific journal


• Subarachnoid Hemorrhaging with Multiple Cerebral Artery Stenoses after Initiating Remission Induction Therapy for Eosinophilic Granulomatosis with Polyangiitis: a Case Report.

  Haruka Yasuba, Hirotaka Yamada, Masaya Togo, Kento Matoba, Eriko Yamamoto Kashihara, Keisuke Nishimura, Sho Sendo, Yo Ueda, Jun Saegusa

  We encountered a 64-year-old Japanese woman who developed subarachnoid hemorrhaging (SAH) with multiple cerebral artery stenoses during remission induction therapy for eosinophilic granulomatosis and polyangiitis (EGPA). The treatment involved intensified steroid pulse therapy and continued intravenous cyclophosphamide pulse therapy, which led to beneficial effects. Given the rarity of multiple EGPA-associated cerebral artery stenoses and SAH, it is crucial to differentiate them from other diseases. The mortality rate of EGPA complicated by intracranial hemorrhagic lesions, including SAH, is high. When headache is present at the onset of EGPA, the possibility of SAH must be considered.

  May 2024, Internal medicine (Tokyo, Japan), 63(24) (24), 3389 - 3394, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Impact of anti-squamous cell carcinoma antigen antibodies on serum squamous cell carcinoma antigen levels measured by chemiluminescent immunoassay and chemiluminescent enzyme immunoassay.

  Chinami Oyabu, Itsuko Sato, Mari Yamamoto, Takamitsu Imanishi, Sho Sendo, Yoshihiko Yano

  OBJECTIVE: The serum squamous cell carcinoma antigen (SCCA) level is a well-known tumor marker for squamous cell carcinoma. In this study, we examined the impact of immunoglobulin (Ig)-bound macromolecular SCCA on serum SCCA levels measured by 2 different methods. METHODS: Seventy-five serum samples with an SCCA level >5.0 ng/mL as determined by a chemiluminescent immunoassay (CLIA) were also analyzed using a chemiluminescent enzyme immunoassay (CLEIA). The levels of IgG- and IgA-type anti-SCCA antibodies, which form immunoglobulins and macromolecules, respectively, were determined using an enzyme-linked immunosorbent assay. An absorption test was performed to confirm the presence of anti-SCCA antibodies. RESULTS: The correlation coefficient between the values measured by CLEIA and CLIA was 0.768. The ratio of SCCA levels measured by CLEIA to those measured by CLIA in 14 samples with IgG-type anti-SCCA antibodies was significantly lower than that in samples without these antibodies (P < .031). Absorption tests showed that SCCA levels measured by CLIA might be falsely high in samples with IgG-type anti-SCCA antibodies, probably due to reactions with SCCA1. CONCLUSION: The level of SCCA as measured by CLIA and CLEIA methods correlate well, but the presence of SCCA antibodies can affect the results of the CLIA method.

  May 2024, Laboratory medicine, 55(3) (3), 341 - 346, English, International magazine

  Scientific journal


• Association of large joint involvement at the start of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors with disease activity and drug retention in patients with rheumatoid arthritis: The ANSWER cohort study.

  Iku Shirasugi, Akira Onishi, Keisuke Nishimura, Wataru Yamamoto, Kosaku Murakami, Hideo Onizawa, Yuichi Maeda, Kosuke Ebina, Yonsu Son, Hideki Amuro, Masaki Katayama, Ryota Hara, Koji Nagai, Yuri Hiramatsu, Motomu Hashimoto, Tadashi Okano, Toshihisa Maeda, Shinya Hayashi, Sho Sendo, Sadao Jinno, Yuzuru Yamamoto, Hirotaka Yamada, Yo Ueda, Jun Saegusa

  AIM: To investigate the association of large joint involvement (LJI) with disease activity and drug retention in patients with rheumatoid arthritis (RA) who started receiving a biological disease-modifying antirheumatic drug or Janus kinase inhibitor. METHODS: Patients with RA from a Japanese multicenter observational registry were enrolled. Our definition of large joints included the shoulder, elbow, hip, knee, and ankle joints. Linear mixed-effects models were used to examine changes in the clinical disease activity index (CDAI) score at Week 24 as the primary outcome, and drug retention rates were compared between patients with and without LJI using Cox proportional hazards models. We examined the potential effect modifications of changes in the CDAI by baseline characteristics. RESULTS: Overall, 2507 treatment courses from 1721 patients were included (LJI, 1744; no LJI, 763). Although LJI was associated with significantly higher changes in CDAI from baseline at Week 24 (difference in change in CDAI: -5.84 [-6.65 to -5.03], p < .001), CDAI was significantly higher in patients with LJI over time. Retention rates were similar in both groups. The association of LJI with changes in disease activity was more prominent in patients with a short disease duration, negative anti-citrullinated peptide antibodies, and interleukin-6 receptor inhibitor (IL-6Ri) use. CONCLUSION: Although LJI was associated with a greater reduction in disease activity from baseline, higher disease activity at baseline was not offset over time in patients with LJI, demonstrating that LJI is an unfavorable predictor. An early treat-to-target strategy using an IL-6Ri may be beneficial for patients with LJI.

  Mar. 2024, International journal of rheumatic diseases, 27(3) (3), e15097, English, International magazine

  [Refereed]

  Scientific journal


• Myeloid-derived suppressor cell-derived osteoclasts with bone resorption capacity in the joints of arthritic SKG mice.

  Yoshikazu Fujikawa, Sho Sendo, Alfonso Del Peral Fanjul, Hirotaka Yamada, Kenichi Uto, Yuzuru Yamamoto, Takumi Nagamoto, Akio Morinobu, Jun Saegusa

  BACKGROUND: Myeloid-derived suppressor cells (MDSCs) are heterogeneous immature myeloid cells with immunosuppressive functions. It is known that MDSCs are expanded at inflammatory sites after migrating from bone marrow (BM) or spleen (Sp). In chronic inflammatory diseases such as rheumatoid arthritis (RA), previous reports indicate that MDSCs are increased in BM and Sp, but detailed analysis of MDSCs in inflamed joints is very limited. OBJECTIVE: The purpose of this study is to characterize the MDSCs in the joints of mice with autoimmune arthritis. METHODS: We sorted CD11b+Gr1+ cells from joints (Jo), bone marrow (BM) and spleen (Sp) of SKG mice with zymosan (Zym)-induced arthritis and investigated differentially expressed genes (DEGs) by microarray analysis. Based on the identified DEGs, we assessed the suppressive function of CD11b+Gr1+ cells from each organ and their ability to differentiate into osteoclasts. RESULTS: We identified MDSCs as CD11b+Gr1+ cells by flow cytometry and morphological analysis. Microarray analysis revealed that Jo-CD11b+Gr1+ cells had different characteristics compared with BM-CD11b+Gr1+ cells or Sp-CD11b+Gr1+ cells. Microarray and qPCR analysis showed that Jo-CD11b+Gr1+ cells strongly expressed immunosuppressive DEGs (Pdl1, Arg1, Egr2 and Egr3). Jo-CD11b+Gr1+ cells significantly suppressed CD4+ T cell proliferation and differentiation in vitro, which confirmed Jo-CD11b+Gr1+ cells as MDSCs. Microarray analysis also revealed that Jo-MDSCs strongly expressed DEGs of the NF-κB non-canonical pathway (Nfkb2 and Relb), which is relevant for osteoclast differentiation. In fact, Jo-MDSCs differentiated into osteoclasts in vitro and they had bone resorptive function. In addition, intra-articular injection of Jo-MDSCs promoted bone destruction. CONCLUSIONS: Jo-MDSCs possess a potential to differentiate into osteoclasts which promote bone resorption in inflamed joints, while they are immunosuppressive in vitro.

  2024, Frontiers in immunology, 15, 1168323 - 1168323, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Impact of dysregulated microbiota-derived C18 polyunsaturated fatty acid metabolites on arthritis severity in mice with collagen-induced arthritis.

  Katsuhiko Yoneda, Sho Sendo, Takaichi Okano, Hidenori Shimizu, Hirotaka Yamada, Keisuke Nishimura, Yo Ueda, Jun Saegusa

  OBJECTIVE: We aimed to evaluate microbiome and microbiota-derived C18 dietary polyunsaturated fatty acids (PUFAs), such as conjugated linoleic acid (CLA), and to investigate their differences that correlate with arthritis severity in collagen-induced arthritis (CIA) mice. METHODS: On day 84 after induction, during the chronic phase of arthritis, cecal samples were analyzed using 16S rRNA sequencing, and plasma and cecal digesta were evaluated using liquid chromatography-tandem mass spectrometry. Differences in microbial composition between 10 control (Ctrl) and 29 CIA mice or between the mild and severe subgroups based on arthritis scores were identified. The cecal metabolite profile and its correlation with the microbiome were evaluated with respect to arthritis severity. RESULTS: The hydroxy and oxo metabolite levels were higher in CIA mice than in Ctrl mice, some of which, including 10-hydroxy-cis-6-18:1, were positively correlated with arthritis scores. The 9-trans,11-trans CLA levels in CIA mice had a negative linear correlation with arthritis scores. Microbial diversity was lower in severe CIA mice than in mild CIA or Ctrl mice. The abundance of Lactobacillus relatively increased in the severe subgroup of CIA mice compared with that in the mild subgroup and was positively correlated with arthritis severity. CONCLUSION: Alterations in gut microbiota and microbiota-derived C18 PUFA metabolites are associated in CIA mice and correlated with arthritis scores, indicating that plasma or fecal C18 PUFA metabolites can be potential biomarkers for arthritis severity and dysbiosis.

  2024, Frontiers in immunology, 15, 1444892 - 1444892, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Trends of disease activity in Japanese patients over 75 years with rheumatoid arthritis from 2014 to 2021- the ANSWER cohort study.

  Hirotaka Yamada, Sadao Jinno, Toshihisa Maeda, Shinya Hayashi, Wataru Yamamoto, Akira Onishi, Hideo Onizawa, Tohru Takeuchi, Yuri Hiramatsu, Yasutaka Okita, Kosuke Ebina, Yonsu Son, Naofumi Yoshida, Ryu Watanabe, Ryota Hara, Mai Yamashita, Yoko Nose, Yuzuru Yamamoto, Takaichi Okano, Keisuke Nishimura, Yo Ueda, Sho Sendo, Motomu Hashimoto, Ryosuke Kuroda, Jun Saegusa

  OBJECTIVES: To investigate if disease activity among elderly RA patients over 75 years has changed over time in the real-world clinical setting. METHODS: Data from an observational multicentre registry of RA patients in Japan were analyzed. The primary outcome was to evaluate the changes in the proportion of very elderly RA patients (over 75 years) who achieved remission and low disease activity, from 2014 to 2021. The secondary outcome was to identify factors associated with remission and low disease activity by comparing demographic and clinical characteristics among the patients who had a study visit within the study period, using multivariate logistic regression. RESULTS: A total of 32 161 patient visits were identified from 2014 to 2021. The proportion of patients over 75 years increased from 16.5% to 26.9%, with biologics and targeted-synthetic disease modifying anti-rheumatic drugs (b/tsDMARDs) usage increasing and glucocorticoids usage decreasing, while conventional-synthetic DMARDs usage remained relatively stable. The proportion of RA patients over 75 years achieving remission and low disease activity significantly increased from 62.2% to 78.2% (p for trend < 0.001). A negative factor associated with achieving remission and low disease activity was glucocorticoid usage, seropositivity, and history of previous b/tsDMARDs use while MTX usage was associated positively, independent of other predictors. CONCLUSIONS: In our cohort, disease activity among very elderly RA patients has improved over time. The study suggests the importance of using a treat-to-target approach in very elderly RA patients to improve clinical outcomes.

  Oct. 2023, Rheumatology (Oxford, England), 63(8) (8), 2147 - 2151, English, International magazine

  [Refereed]

  Scientific journal


• Clustering of phosphatase RPTPα promotes Src signaling and the arthritogenic action of synovial fibroblasts.

  Sho Sendo, William B Kiosses, Shen Yang, Dennis J Wu, Daniel W K Lee, Lin Liu, Yael Aschner, Allison J Vela, Gregory P Downey, Eugenio Santelli, Nunzio Bottini

  Receptor-type protein phosphatase α (RPTPα) promotes fibroblast-dependent arthritis and fibrosis, in part, by enhancing the activation of the kinase SRC. Synovial fibroblasts lining joint tissue mediate inflammation and tissue damage, and their infiltration into adjacent tissues promotes disease progression. RPTPα includes an ectodomain and two intracellular catalytic domains (D1 and D2) and, in cancer cells, undergoes inhibitory homodimerization, which is dependent on a D1 wedge motif. Through single-molecule localization and labeled molecule interaction microscopy of migrating synovial fibroblasts, we investigated the role of RPTPα dimerization in the activation of SRC, the migration of synovial fibroblasts, and joint damage in a mouse model of arthritis. RPTPα clustered with other RPTPα and with SRC molecules in the context of actin-rich structures. A known dimerization-impairing mutation in the wedge motif (P210L/P211L) and the deletion of the D2 domain reduced RPTPα-RPTPα clustering; however, it also unexpectedly reduced RPTPα-SRC association. The same mutations also reduced recruitment of RPTPα to actin-rich structures and inhibited SRC activation and cellular migration. An antibody against the RPTPα ectodomain that prevented the clustering of RPTPα also inhibited RPTPα-SRC association and SRC activation and attenuated fibroblast migration and joint damage in arthritic mice. A catalytically inactivating RPTPα-C469S mutation protected mice from arthritis and reduced SRC activation in synovial fibroblasts. We conclude that RPTPα clustering retains it to actin-rich structures to promote SRC-mediated fibroblast migration and can be modulated through the extracellular domain.

  Jul. 2023, Science signaling, 16(792) (792), eabn8668, English, International magazine

  Scientific journal


• Pressure Ulcer in Three Cases of Anit-MDA5 Antibody Positive Dermatomyositis

  福満祥子, 新川衣里子, 鷲尾健, 明石健吾, 岡野隆一, 千藤荘, 森信暁雄, 小野竜輔, 永井宏, 錦織千佳子

  2022, 西日本皮膚科, 84(2) (2)


• Effect of resolvin D5 on T cell differentiation and osteoclastogenesis analyzed by lipid mediator profiling in the experimental arthritis.

  Hirotaka Yamada, Jun Saegusa, Sho Sendo, Yo Ueda, Takaichi Okano, Masakazu Shinohara, Akio Morinobu

  Resolvins, are specialized pro-resolving mediators (SPMs) derived from n-3 polyunsaturated fatty acids. They contribute actively to the resolution of inflammation, but little is known concerning their role in chronic inflammation, such as in rheumatoid arthritis (RA). Here, we performed lipid mediator (LM) profiling in tissues from the paws of SKG arthritic mice using lipid chromatography (LC)/mass spectrometry (MS)/MS-based LM metabololipidomics. We found elevated levels of SPMs including resolvin D5 (RvD5) in these tissues. Moreover, RvD5 levels were significantly correlated with arthritis disease activity. From experiments to assess the role of RvD5 in the pathology of RA, we concluded that RvD5 suppressed Th17 cell differentiation and facilitated regulatory T cell differentiation, as well as inhibiting CD4+ T cell proliferation. Furthermore, RvD5 attenuated osteoclast differentiation and interfered with osteoclastogenesis. Targeting the resolution of inflammation could be promising as a novel treatment for RA.

  Aug. 2021, Scientific reports, 11(1) (1), 17312 - 17312, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Treatment with an Anti-CX3CL1 Antibody Suppresses M1 Macrophage Infiltration in Interstitial Lung Disease in SKG Mice.

  Satoshi Mizutani, Junko Nishio, Kanoh Kondo, Kaori Motomura, Zento Yamada, Shotaro Masuoka, Soichi Yamada, Sei Muraoka, Naoto Ishii, Yoshikazu Kuboi, Sho Sendo, Tetuo Mikami, Toshio Imai, Toshihiro Nanki

  CX3C Motif Chemokine Ligand 1 (CX3CL1; fractalkine) has been implicated in the pathogenesis of rheumatoid arthritis (RA) and its inhibition was found to attenuate arthritis in mice as well as in a clinical trial. Therefore, we investigated the effects of an anti-CX3CL1 monoclonal antibody (mAb) on immune-mediated interstitial lung disease (ILD) in SKG mice, which exhibit similar pathological and clinical features to human RA-ILD. CX3CL1 and CX3C chemokine receptor 1 (CX3CR1), the receptor for CX3CL1, were both expressed in the fibroblastic foci of lung tissue and the number of bronchoalveolar fluid (BALF) cells was elevated in ILD in SKG mice. No significant changes were observed in lung fibrosis or the number of BALF cells by the treatment with anti-CX3CL1 mAb. However, significantly greater reductions were observed in the number of M1 macrophages than in M2 macrophages in the BALF of treated mice. Furthermore, CX3CR1 expression levels were significantly higher in M1 macrophages than in M2 macrophages. These results suggest the stronger inhibitory effects of the anti-CX3CL1 mAb treatment against the alveolar infiltration of M1 macrophages than M2 macrophages in ILD in SKG mice. Thus, the CX3CL1-CX3CR1 axis may be involved in the infiltration of inflammatory M1 macrophages in RA-ILD.

  May 2021, Pharmaceuticals (Basel, Switzerland), 14(5) (5), English, International magazine

  Scientific journal


• Soluble guanylate cyclase stimulator reduced the gastrointestinal fibrosis in bleomycin-induced mouse model of systemic sclerosis.

  Yuzuru Yamamoto, Takaichi Okano, Hirotaka Yamada, Kengo Akashi, Sho Sendo, Yo Ueda, Akio Morinobu, Jun Saegusa

  BACKGROUND: Systemic sclerosis (SSc) is a chronic autoimmune-mediated connective tissue disorder. Although the etiology of the disease remains undetermined, SSc is characterized by fibrosis and proliferative vascular lesions of the skin and internal organs. SSc involves the gastrointestinal tract in more than 90 % of patients. Soluble guanylate cyclase (sGC) stimulator is used to treat pulmonary artery hypertension (PAH) and has been shown to inhibit experimental skin fibrosis. METHODS: Female C57BL/6J mice were treated with BLM or normal saline by subcutaneous implantation of osmotic minipump. These mice were sacrificed on day 28 or day 42. Gastrointestinal pathologies were examined by Masson Trichrome staining. The expression of fibrosis-related genes in gastrointestinal tract was analyzed by real-time PCR, and the levels of collagen in the tissue were measured by Sircol collagen assay. To evaluate peristaltic movement, the small intestinal transport (ITR%) was calculated as [dyeing distance × (duodenum - appendix)] - 1 × 100 (%). We treated BLM-treated mice with sGC stimulator or DMSO orally and analyzed them on day 42. RESULTS: Histological examination revealed that fibrosis from lamina propria to muscularis mucosa in the esophagus was significantly increased in BLM-treated mice, suggesting that BLM induces esophageal hyperproliferative and prefibrotic response in C57BL/6J mice. In addition, the gene expression levels of Col3a1, CCN2, MMP-2, MMP-9, TIMP-1, and TIMP-2 in the esophagus were significantly increased in BLM-treated mice. More severe hyperproliferative and prefibrotic response was observed in the mice sacrificed on day 42 than the mice sacrificed on day 28. The ITR% was found to be significantly lower in BLM-treated mice, suggesting that gastrointestinal peristaltic movement was reduced in BLM-treated mice. Furthermore, we demonstrated that sGC stimulator treatment significantly reduced hyperproliferative and prefibrotic response of esophagus and intestine in BLM-treated mice, by histological examination and Sircol collagen assay. CONCLUSIONS: These findings suggest that BLM induces gastrointestinal hyperproliferative and prefibrotic response in C57BL/6J mice, and treatment with sGC stimulator improves the BLM-induced gastrointestinal lesion.

  May 2021, Arthritis research & therapy, 23(1) (1), 133 - 133, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 赤血球中ポリグルタミル化メトトレキサートに影響を与える臨床指標と肝障害の研究

  高橋 未帆, 齋藤 敏晴, 森 あやの, 柴田 美帆, 西田 美和, 高橋 宗史, 旗智 さおり, 千藤 荘, 辻 剛, 熊谷 俊一

  (一社)日本臨床検査医学会, Oct. 2019, 臨床病理, 67(補冊) (補冊), 255 - 255, Japanese


• Subjective well-being among rheumatoid arthritis patients.

  Goichi Kageyama, Akira Onishi, Yo Ueda, Ikuko Naka, Kosaku Tsuda, Takaichi Okano, Kengo Akashi, Keisuke Nishimura, Sho Sendo, Jun Saegusa, Akio Morinobu

  AIM: Subjective well-being (SWB) is a psychological construct that is synonymous with happiness. Many variables including age, sex, income, employment, and marital status are related to SWB. Health is also an important determinant of SWB that can be adversely affected in patients with chronic conditions such as rheumatoid arthritis (RA). In this study, we evaluate the SWB of RA patients and compare it with that of healthy controls. METHODS: We obtained the original dataset from the "Quality of Life Survey, 2013", which was conducted by the Economic and Social Research Institute, Cabinet Office, Government of Japan. In this survey, SWB was determined by asking participants to rate their happiness between 0 (very unhappy) and 10 (very happy). The survey also included a 56-point questionnaire regarding well-being-related variables. This questionnaire was administered to RA patients recruited from Kobe University Hospital, and clinical and treatment data were simultaneously collected. RESULTS: Multivariate analysis revealed that RA patients with high or moderate disease activity had SWB scores that were similar to those of controls. However, the SWB scores of RA patients in remission or with low disease activity were higher than those of controls (P = .013). SWB was associated with household income, self-assessment of living costs, self-assessment of health, depression/ anxiety, and social connection. CONCLUSIONS: For RA patients, achieving the therapeutic target can result in better SWB than that of healthy controls. Financial status, self-assessment of health, psychological stress, and social network are also important determinants for the SWB of RA patients.

  Oct. 2019, International journal of rheumatic diseases, 22(10) (10), 1863 - 1870, English, International magazine

  Scientific journal


• Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice.

  Sho Sendo, Jun Saegusa, Hirotaka Yamada, Keisuke Nishimura, Akio Morinobu

  BACKGROUND: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a sometimes life-threatening complication in RA patients. SKG mice develop not only arthritis but also an ILD resembling RA-ILD. We previously reported that tofacitinib, a JAK inhibitor, facilitates the expansion of myeloid-derived suppressor cells (MDSCs) and ameliorates arthritis in SKG mice. The aim of this study was to elucidate the effect of tofacitinib on the ILD in SKG mice. METHODS: We assessed the effect of tofacitinib on the zymosan (Zym)-induced ILD in SKG mice histologically and examined the cells infiltrating the lung by flow cytometry. The effects of lung MDSCs on T cell proliferation and Th17 cell differentiation were assessed in vitro. We also evaluated the effects of tofacitinib on MDSCs and dendritic cells in vitro. RESULTS: Tofacitinib significantly suppressed the progression of ILD compared to the control SKG mice. The MDSCs were increased, while Th17 cells, group 1 innate lymphoid cells (ILC1s), and GM-CSF+ILCs were decreased in the lungs of tofacitinib-treated mice. MDSCs isolated from the inflamed lungs suppressed T cell proliferation and Th17 cell differentiation in vitro. Tofacitinib promoted MDSC expansion and suppressed bone marrow-derived dendritic cell (BMDC) differentiation in vitro. CONCLUSION: Tofacitinib facilitates the expansion of MDSCs in the lung and ameliorates ILD in SKG mice.

  Aug. 2019, Arthritis research & therapy, 21(1) (1), 184 - 184, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Additive effects of inhibiting both mTOR and glutamine metabolism on the arthritis in SKG mice.

  Yo Ueda, Jun Saegusa, Takaichi Okano, Sho Sendo, Hirotaka Yamada, Keisuke Nishimura, Akio Morinobu

  Glutamine metabolism and the mechanistic target of rapamycin (mTOR) pathway are activated cooperatively in the differentiation and activation of inflammatory immune cells. But the combined inhibition of both pathways was rarely investigated. This study investigated how inhibiting both glutamine metabolism with 6-diazo-5-oxo-L-norleucine (DON) and mTOR with rapamycin affects immune cells and the arthritis in a mouse model. We revealed that rapamycin and DON additively suppressed CD4+ T cell proliferation, and both of them inhibited Th17 cell differentiation. While DON inhibited the differentiation of dendritic cells and macrophages and facilitated that of Ly6G+ granulocytic (G)-MDSCs more strongly than did rapamycin, G-MDSCs treated with rapamycin but not DON suppressed CD4+ T cell proliferation in vitro. The combination of rapamycin and DON significantly suppressed the arthritis in SKG mice more strongly than did each monotherapy in vivo. The numbers of CD4+ T and Th17 cells in the spleen were lowest in mice treated with the combination therapy. Thus, combined treatment with rapamycin and DON additively ameliorated the arthritis in SKG mice, possibly by suppressing CD4+ T cell proliferation and Th17 differentiation. These results suggest the combination of rapamycin and DON may be a potential novel therapy for arthritis.

  Apr. 2019, Scientific reports, 9(1) (1), 6374 - 6374, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Acute Pulmonary Hypertension Crisis after Adalimumab Reduction in Rheumatoid Vasculitis.

  Gentaro Yamasaki, Mitsumasa Okano, Kazuhiko Nakayama, Naoe Jimbo, Sho Sendo, Naoki Tamada, Kenta Misaki, Yuto Shinkura, Kenichi Yanaka, Hidekazu Tanaka, Kengo Akashi, Akio Morinobu, Hiroshi Yokozaki, Noriaki Emoto, Ken-Ichi Hirata

  Rheumatoid vasculitis is a rare etiology for pulmonary hypertension (PH) in patients with connective tissue disease. We encountered a case of acute PH crisis in a case with rheumatoid vasculitis eight months after undergoing adalimumab reduction. Since no repetition of arthralgia occurred after the adalimumab reduction, we decided to not increase the dose of adalimumab. However, hemodynamic collapse thereafter developed and even though steroid pulse therapy was administered, the patient nevertheless died. The autopsy showed clusters of acute and chronic inflammation around the remodeled pulmonary arteries along with micro-thrombi in the vessel lumen. We should consider the possibility of critical worsening of PH as a phenotype of vasculitis related to immunosuppressive therapy reduction.

  2019, Internal medicine (Tokyo, Japan), 58(4) (4), 593 - 601, English, Domestic magazine

  Scientific journal


• CD11b+Gr-1dim Tolerogenic Dendritic Cell-Like Cells Are Expanded in Interstitial Lung Disease in SKG Mice.

  Sho Sendo, Jun Saegusa, Takaichi Okano, Soshi Takahashi, Kengo Akashi, Akio Morinobu

  OBJECTIVE: SKG mice develop interstitial lung disease (ILD) resembling rheumatoid arthritis-associated ILD in humans. The aim of this study was to clarify the mechanism underlying the lung pathology by analyzing lung-infiltrating cells in SKG mice with ILD. METHODS: We assessed the severity of zymosan A (ZyA)-induced ILD in SKG mice histologically, and we examined lung-infiltrating cells by flow cytometry. Total lung cells and isolated monocytic myeloid-derived suppressor cells (MDSCs) were cultured in vitro with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4. The proliferation of 5,6-carboxyfluorescein diacetate N-succinimidyl ester-labeled naive T cells cocultured with isolated CD11b+Gr-1dim cells and MDSCs was evaluated by flow cytometry. CD11b+Gr-1dim cells were adoptively transferred to ZyA-treated SKG mice. RESULTS: MDSCs, Th17 cells, and group 1 and 3 innate lymphoid cells (ILC1s and ILC3s) were increased in the lungs; the proportion of these cells varied with ILD severity. In this process, we found that a unique cell population, CD11b+Gr-1dim cells, was expanded in the severely inflamed lungs. Approximately half of the CD11b+Gr-1dim cells expressed CD11c. CD11b+Gr-1dim cells were induced from monocytic MDSCs with GM-CSF in vitro and were considered tolerogenic because they suppressed T cell proliferation. These CD11b+Gr-1dim cells have never been described previously, and we termed them CD11b+Gr-1dim tolerogenic dendritic cell (DC)-like cells. Th17 cells, ILC1s, and ILC3s in the inflamed lung produced GM-CSF, which may have expanded CD11b+Gr-1dim tolerogenic DC-like cells in vivo. Furthermore, adoptive transfer of CD11b+Gr-1dim tolerogenic DC-like cells significantly suppressed progression of ILD in SKG mice. CONCLUSION: We identified unique suppressive myeloid cells that were differentiated from monocytic MDSCs in SKG mice with ILD, and we termed them CD11b+Gr-1dim tolerogenic DC-like cells.

  Dec. 2017, Arthritis & rheumatology (Hoboken, N.J.), 69(12) (12), 2314 - 2327, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• IgG4-related disease manifesting as pericarditis with elevated adenosine deaminase and IL-10 levels in pericardial fluid.

  Sho Sendo, Jun Saegusa, Yukiko Morinaga, Fumi Kawakami, Yoshinori Kogata, Goichi Kageyama, Akio Morinobu

  A 78-year-old female with massive pericardial effusion fulfilled diagnostic criteria for immunoglobulin G4 (IgG4)-related disease. Although her adenosine deaminase (ADA) level in the pericardial effusion was high, all the tests for tuberculosis infection were negative. Immunostaining of the pericardium biopsy specimen revealed remarkably increased IgG4-positive cells. This is the first report describing IgG4-related pericarditis with elevated ADA level. We also demonstrate the elevated interleukin-10 (IL-10) level in pericardial fluid and IL-10-producing T-cells in the pericardium.

  Sep. 2017, Modern rheumatology, 27(5) (5), 894 - 897, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Glutaminase 1 plays a key role in the cell growth of fibroblast-like synoviocytes in rheumatoid arthritis.

  Soshi Takahashi, Jun Saegusa, Sho Sendo, Takaichi Okano, Kengo Akashi, Yasuhiro Irino, Akio Morinobu

  Apr. 2017, Arthritis research & therapy, 19(1) (1), 76 - 76, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 3-bromopyruvate ameliorate autoimmune arthritis by modulating Th17/Treg cell differentiation and suppressing dendritic cell activation.

  Takaichi Okano, Jun Saegusa, Keisuke Nishimura, Soshi Takahashi, Sho Sendo, Yo Ueda, Akio Morinobu

  Feb. 2017, Scientific reports, 7, 42412 - 42412, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Knockout of endothelin type B receptor signaling attenuates bleomycin-induced skin sclerosis in mice.

  Kengo Akashi, Jun Saegusa, Sho Sendo, Keisuke Nishimura, Takuya Okano, Keiko Yagi, Masashi Yanagisawa, Noriaki Emoto, Akio Morinobu

  May 2016, Arthritis research & therapy, 18(1) (1), 113 - 113, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 関節リウマチの活動性把握における血清MMP-3測定の有用性

  上村 裕子, 林 秀敏, 高橋 敏夫, 齋藤 敏晴, 梅田 良祐, 一瀬 良英, 千藤 荘, 辻 剛, 熊谷 俊一

  関節リウマチ(RA)206例と健常者196例を対象に、CRP、SAA、ESR、DAS28(CRP)及びDAS28(ESR)と血清マトリクスメタロプロテナーゼ-3(MMP-3)との関連について検討した。その結果、RA患者ではいずれも血清MMP-3と有意の正相関を認めた。次に、ヨーロッパリウマチ学会の活動性基準により、寛解、低活動性、中等度活動性、高活動性の4群に分け検討した。その結果、疾患活動性の上昇に伴い血清MMP-3も有意に増加した。更に、女性RA患者173例について、DAS28の構成成分である疼痛関節数(TJC)、腫脹関節数(SJC)、全般的健康状態(患者VAS)との関連について検討した。その結果、いずれも血清MMP-3と有意の正相関を認めた。治療との関係については、メトトレキサートやインフリキシマブ投与前後で血清MMP-3は有意に低下した。血清MM-P3は関節障害や治療反応性の予測マーカーとして有用と考えられた。

  (一社)日本臨床検査医学会, Dec. 2015, 臨床病理, 63(12) (12), 1357 - 1364, Japanese


• [MMP-3 as a Biomarker of Disease Activity of Rheumatoid Arthritis].

  Yuko Uemura, Hidetoshi Hayashi, Toshio Takahashi, Toshiharu Saitho, Ryousuke Umeda, Yoshihide Ichise, Sho Sendo, Goh Tsuji, Shunichi Kumagai

  The aim of this study was to confirm the clinical significance of serum MMP-3 measurement in the evalua- tion of disease activity and effectiveness of treatment in patients with rheumatoid arthritis (RA). MMP-3 was measured for 206 outpatients with RA during a period of 4 months, and also serially measured for RA patients treated with methotrexate(MTX) alone or together with infliximab (IFX). Serum MMP-3 was significantly correlated with CRP, SAA, and ESR. Significant correlation of serum MMP-3 was found not only with DAS28 (CRP) in female and male patients (p <0.0001 and p < 0.0051, respectively) but also with the EULAR classification criteria for the disease activity of RA. Among the items of DAS28(CRP), the strongest association of MMP-3 was found with swollen joint counts. Furthermore, MMP-3 levels increased with advances in Stage and Class of RA. MMP-3 levels gradually decreased 12 and 24 weeks after successful treatment with MTX (p=0.0188 and p=0.0179, respectively). Extent of the decrease was more prominent in patients with better response to MTX than in those with poor response. MMP-3 levels significantly decreased 6 weeks after IFX treatment and continued to decrease until 48 weeks. Significant decrease of MMP-3 level from before treatment was shown only in the good response group to IFX after 48 weeks of treatment. MMP-3 level was shown to be useful as a disease activity marker in RA patients. In addition, serial measurement of MMP-3 maybe helpful to evaluate the effect of treatments with MTX and IFX.

  Dec. 2015, Rinsho byori. The Japanese journal of clinical pathology, 63(12) (12), 1357 - 64, Japanese, Domestic magazine

  Scientific journal


• Metabolomics analysis of saliva from patients with primary Sjögren's syndrome.

  G Kageyama, J Saegusa, Y Irino, S Tanaka, K Tsuda, S Takahashi, S Sendo, A Morinobu

  The recent development of salivary proteomics has led to the identification of potential biomarkers for diagnosing patients with primary Sjögren's syndrome (pSS). Here we sought to identify differentially produced salivary metabolites from pSS patients and healthy controls (HCs) that might be used to characterize this disease. We obtained salivary samples from 12 female pSS patients (mean age 44.2 ± 13.01) and 21 age-matched female HCs. The metabolite profiles of saliva were analysed by gas chromatography-mass spectrometry. The total metabolite levels in each of the samples were calculated and compared across the study participants. A total of 88 metabolites were detected across the study samples, 41 of which were observed at reduced levels in the samples from pSS patients. Principal component analysis (PCA) revealed a loss in salivary metabolite diversity in the pSS patient samples compared to the HC samples. The reduced presence of glycine, tyrosine, uric acid and fucose, which may reflect salivary gland destruction due to chronic sialoadenitis, contributed to the loss of diversity. Comparative PCA of the pSS patients revealed the presence of two subpopulations based on their metabolite profiles, and these two subpopulations showed a significant difference in the prevalence of major salivary glanditis (P = 0.014). In this study, we found that the salivary metabolite profile of pSS patients was less diverse than that of HCs and that the metabolite profiles in pSS patients were affected by the presence of major salivary glanditis.

  Nov. 2015, Clinical and experimental immunology, 182(2) (2), 149 - 53, English, International magazine

  Scientific journal


• Granulomatosis with polyangiitis (Wegener's granulomatosis) diagnosed by transbronchial biopsy from stenotic portion of mainstem bronchus.

  Sho Sendo, Goh Tsuji, Ryosuke Umeda, Yoshihide Ichise, Shunichi Kumagai, Yujiro Suzuki

  This report concerns a case of granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis (WG)) with bronchus narrowing. Although nasal biopsy had been performed three times, no positive histology for GPA (WG) could be obtained. Flexible bronchoscopy revealed diffuse erythema, edema of the mucosa and stenosis of the right mainstem bronchus. Transbronchial biopsy identified granuloma with giant cells. These findings led to a diagnosis of GPA (WG). This case suggests that biopsy from the bronchus is useful for diagnosis of GPA (WG).

  Jul. 2015, Modern rheumatology, 25(4) (4), 649 - 52, English, International magazine

  Scientific journal


• Epidural spinal tumor and periaortitis as rare complications of Wegener's granulomatosis.

  Shimpei Kasagi, Jun Saegusa, Goh Tsuji, Sho Sendo, Natsuko Miura, Hiroki Hayashi, Takeshi Sugimoto, Seiji Kawano, Kotaro Nishida, Kenichiro Kakutani, Akio Morinobu, Shunichi Kumagai

  This case report describes findings in a 61-year-old woman who manifested scleritis, small pulmonary nodules, otitis media, periaortitis, and progressive epidural spinal tumor, associated with elevated serum myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA) levels. She was clinically diagnosed with Wegener's granulomatosis, although vasculitis was not diagnosed due to the lack of typical histological findings. We discuss the differential diagnosis in this patient, and the association of MPO-ANCA with periaortitis or epidural spinal tumor.

  Dec. 2011, Modern rheumatology, 21(6) (6), 678 - 83, English, International magazine

  Scientific journal


• Role of imaging studies in the diagnosis and evaluation of giant cell arteritis in Japanese: report of eight cases.

  Akio Morinobu, Goh Tsuji, Shimpei Kasagi, Jun Saegusa, Hiroki Hayashi, Takashi Nakazawa, Yoshinori Kogata, Kenta Misaki, Keisuke Nishimura, Sho Sendo, Natsuko Miura, Seiji Kawano, Shunichi Kumagai

  The objective of this study is to clarify the characteristics and imaging results of Japanese patients with giant cell arteritis (GCA). Eight patients with biopsy-proven GCA were enrolled. Their clinical data and imaging results were retrospectively examined from their medical records. All the patients met the criteria for the classification of GCA by the American College of Rheumatology. Although the clinical manifestations are similar to those previously reported, none of the eight patients presented ocular symptoms, and half of them presented jaw claudication. Ultrasonography (US) of temporal artery showed the halo sign in all the patients. Fluorodeoxyglucose positron emission tomography (FDG-PET) was performed in four patients and indicated the presence of aortitis of the patients. US is a quick and noninvasive test to detect inflammation of temporal artery, and FDG-PET is very helpful for early diagnosis of aortitis in GCA. Awareness of the disease and appropriate imaging tests will result in diagnosis of GCA.

  Aug. 2011, Modern rheumatology, 21(4) (4), 391 - 6, English, International magazine

  Scientific journal


• Administration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events.

  Sachiyo Sugiura, Daijo Inaguma, Akimitsu Kitagawa, Minako Murata, Yutaka Kamimura, Sho Sendo, Kyoko Hamaguchi, Hiroshi Nagaya, Miho Tatematsu, Kei Kurata, Yukio Yuzawa, Seiichi Matsuo

  BACKGROUND: Besides its effect on calcium metabolism, vitamin D may play a part in preventing the onset and progression of cardiovascular disease (CVD) events. Only a few reports on the studies relating to whether vitamin D may reduce CVD events in patients with predialysis chronic kidney disease (CKD) are available, and many ambiguities remain. METHODS: We conducted a retrospective cohort study of 665 patients with predialysis CKD. With log-rank test using the Kaplan-Meyer survival curve, comparison of incidences of CVD events, CVD-related mortality, and all-cause mortality were made between patients in the alfacalcidol treatment group (107 patients) in the predialysis stage to whom alfacalcidol 0.25-0.5 microg/day was orally administered for at least 24 weeks, and patients in the nontreatment group (558 patients) who received no administration of alfacalcidol or other type of activated vitamin D and its analogues. Patients to whom alfacalcidol administration was discontinued within 24 weeks as well as initiation of dialysis of <24 weeks were excluded for this study. Factors relating to CVD events were examined using Cox's proportional hazards analysis. RESULTS: The mean follow-up period was 55.1 +/- 38.9 months in the alfacalcidol treatment group and 41.9 +/- 38.4 months in the nontreatment group. CVD events occurred in 172 patients during the follow-up period, and 74 of those occurred during the predialysis period. In the alfacalcidol treatment group, the incidence of cumulative CVD events was significantly lower. In relation to all-cause deaths and CVD-related deaths, the cumulative mortality rate was significantly lower in the alfacalcidol treatment group during the follow-up period. Throughout the follow-up period, the association between CVD events and alfacalcidol use was detected when adjusted for age, sex, diabetes, hypertension, use of renin-angiotensin system inhibitors, estimated glomerular filtration rate, and albumin and parathyroid hormone. CONCLUSION: These data showed that oral administration of alfacalcidol for predialysis CKD patients was associated with reduced risk for CVD.

  Feb. 2010, Clinical and experimental nephrology, 14(1) (1), 43 - 50, English, Domestic magazine

  Scientific journal

• 血小板減少の精査目的で紹介となった60歳代女性—Woman in Her 60s Referred for Evaluation of Thrombocytopenia—第71回学術集会 ; Reversed Clinico-pathological Conference 1 (RCPC1)

  千藤 荘, 志谷 映璃, 宮下 竜伊, 松本 剛, 常川 勝彦

  東京 : 日本臨床検査医学会 = Japanese Society of Laboratory Medicine, Jan. 2026, 日本臨床検査医学会誌 = The journal of Japanese Society of Laboratory Medicine, 74(1) (1), 128 - 133, Japanese


• サボテンの棘の受傷を契機に発症したLomentospora prolificans蜂窩織炎の1症例

  吉田 奈津希, 楠木 まり, 宮良 高維, 千藤 荘

  (一社)日本医真菌学会, Sep. 2025, 日本医真菌学会雑誌, 66(Suppl.1) (Suppl.1), 91 - 91, Japanese


• 血小板減少の精査目的で紹介となった60歳代女性

  千藤 荘, 志谷 映璃, 宮下 竜伊, 松本 剛, 常川 勝彦

  (一社)日本臨床検査医学会, Jul. 2025, 日本臨床検査医学会誌, 73(補冊) (補冊), 099 - 100, Japanese


• 血小板減少の精査目的で紹介となった60歳代女性

  千藤 荘, 志谷 映璃, 宮下 竜伊, 松本 剛, 常川 勝彦

  (一社)日本臨床検査医学会, Jul. 2025, 日本臨床検査医学会誌, 73(補冊) (補冊), 099 - 100, Japanese


• Fib4 indexは関節リウマチ患者においてMTX継続率を予想する

  岡野 隆一, 佐藤 伊都子, 中村 恵宣, 松岡 広, 千藤 荘, 三枝 淳

  (一社)日本臨床検査医学会, Jul. 2025, 日本臨床検査医学会誌, 73(補冊) (補冊), 206 - 206, Japanese


• 尿中アルブミン測定試薬「イムノジェネシスU-ALB」の基礎性能評価

  藤原 淳美, 大籔 智奈美, 渡邉 勇気, 岡崎 葉子, 今西 孝充, 千藤 荘, 矢野 嘉彦

  (一社)日本臨床衛生検査技師会, May 2025, 日本医学検査学会抄録集, 74回, 138 - 138, Japanese


• 当院における病棟検査技師配置に向けての取り組み

  渡邉 勇気, 福住 典子, 大沼 健一郎, 渡邊 優子, 佐藤 伊都子, 今西 孝充, 千藤 荘, 矢野 嘉彦

  (一社)日本臨床衛生検査技師会, May 2025, 日本医学検査学会抄録集, 74回, 407 - 407, Japanese


• 当院における病棟検査技師配置についてのアンケート調査 医師・看護師が実施する検査業務の負担軽減に向けて

  渡邊 優子, 大沼 健一郎, 渡邉 勇気, 福住 典子, 佐藤 伊都子, 今西 孝充, 千藤 荘, 矢野 嘉彦

  (一社)日本臨床衛生検査技師会, May 2025, 日本医学検査学会抄録集, 74回, 408 - 408, Japanese


• 関節リウマチの治療:生物学的製剤1 トシリズマブ使用症例におけるトシリズマブ期間短縮とサリルマブ変更の治療効果の解析 関西多施設ANSWERコホート研究からの報告

  山田 啓貴, 神野 定男, 白杉 郁, 大西 輝, 村上 孝作, 沖田 康孝, 蛯名 耕介, 伊丹 哲, 野崎 祐史, 和田 裕美子, 武内 徹, 渡部 龍, 橋本 求, 西坂 一馬, 能瀬 洋子, 山下 真依, 仲 郁子, 岡野 隆一, 西村 啓佑, 上田 洋, 千藤 荘, 壷坂 正徳, 林 申也, 原 良太, 槇野 秀彦, 孫 瑛洙, 片山 昌紀, 山本 渉, 黒田 良祐, 三枝 淳

  (一社)日本リウマチ学会, Mar. 2025, 日本リウマチ学会総会・学術集会プログラム・抄録集, 69回, 510 - 510, Japanese


• 関節リウマチの治療:DMARDs・NSAIDs・その他1 Fib-4 indexは関節リウマチ患者のメトトレキサート治療において中断のリスク因子となる

  舩津 拓生, 岡野 隆一, Del Peral Fanjul Alfonso, 山下 真依, 白杉 郁, 千藤 荘, 山田 啓貴, 西村 啓佑, 上田 洋, 松岡 広, 三枝 淳

  (一社)日本リウマチ学会, Mar. 2025, 日本リウマチ学会総会・学術集会プログラム・抄録集, 69回, 511 - 511, Japanese


• キャッスルマン病およびTAFRO症候群の病態と治療 TAFRO症候群における治療抵抗性と血小板減少に対する考察 当科で治療した7症例のケースシリーズを通じて

  宮本 千晴, 安井 進太朗, 谷本 幸奈, 藤田 泰佑, 麥谷 道生, 山本 航大, 山田 啓貴, 岡野 隆一, 西村 啓佑, 千藤 荘, 上田 洋, 三枝 淳

  (一社)日本リウマチ学会, Mar. 2025, 日本リウマチ学会総会・学術集会プログラム・抄録集, 69回, 525 - 525, Japanese


• 関節リウマチの治療:DMARDs・NSAIDs・その他 3 高ガンマグロブリン血症を有する関節リウマチ患者における治療反応性の検討 ANSWER cohort study

  仲 郁子, 岡野 隆一, 西坂 一馬, 能瀬 洋子, 山下 真依, 白杉 郁, 山田 啓貴, 西村 啓佑, 千藤 荘, 上田 洋, 壷坂 正徳, 亀長 智幸, 中野 直樹, 林 申也, 山本 渉, 村上 孝作, 大西 輝, 田中 晶大, 孫 瑛洙, 吉川 紋佳, 小谷 卓矢, 冨田 大介, 野崎 祐史, 渡部 龍, 橋本 求, 沖田 康孝, 黒田 良祐, 三枝 淳

  (一社)日本リウマチ学会, Mar. 2025, 日本リウマチ学会総会・学術集会プログラム・抄録集, 69回, 612 - 612, Japanese


• 関節リウマチの治療:tsDMARDs・JAK阻害薬 4 RA予後不良因子におけるJAK阻害薬の臨床的効果について ANSWER cohortによる解析

  野崎 祐史, 村田 浩一, 大西 輝, 辻本 考平, 山田 啓貴, 千藤 荘, 橋本 求, 岡野 匡志, 斯波 秀行, 平松 ゆり, 孫 瑛洙, 吉田 直史, 福田 里香, 森本 祐美, 岸本 和也, 伊丹 哲, 冨田 大介, 芦田 千聖, 志賀 俊彦, 李 進海, 木下 浩二

  (一社)日本リウマチ学会, Mar. 2025, 日本リウマチ学会総会・学術集会プログラム・抄録集, 69回, 644 - 644, Japanese


• 腎機能低下が無い高齢関節リウマチ患者に対してJAK阻害薬を減量投与した場合の効果及び継続率の検討 関西多施設ANSWERコホートを用いた検討

  中野 直樹, 林 申也, 立花 章太郎, 壷坂 正徳, 亀長 智幸, 松本 知之, 西坂 一馬, 能瀬 洋子, 山下 真依, 白杉 郁, 山田 啓貴, 仲 郁子, 岡野 隆一, 西村 啓佑, 上田 洋, 千藤 荘, 山本 渉, 村田 浩一, 藤井 貴之, 岡野 匡志, 橋本 求, 野崎 祐史, 冨田 大介, 小谷 卓矢, 和田 裕美子, 孫 瑛洙, 田中 晶大, 蛯名 耕介, 三枝 淳, 黒田 良祐

  (一社)日本リウマチ学会, Mar. 2025, 日本リウマチ学会総会・学術集会プログラム・抄録集, 69回, 724 - 724, Japanese


• 全身性エリテマトーデス治療中に蛋白漏出性胃腸症を呈したびまん性大細胞型B細胞リンパ腫の1例

  安井 進太朗, 谷本 幸奈, 宮本 千晴, 藤田 泰佑, 麥谷 道生, 山本 航大, 山田 啓貴, 岡野 隆一, 西村 啓佑, 千藤 荘, 上田 洋, 三枝 淳

  (一社)日本リウマチ学会, Mar. 2025, 日本リウマチ学会総会・学術集会プログラム・抄録集, 69回, 728 - 728, Japanese


• 全身性強皮症に対するリツキシマブ投与前後の皮膚超音波を用いた皮膚肥厚変化の評価

  藤田 泰佑, 千藤 荘, 安井 進太朗, 谷本 幸奈, 宮本 千晴, 麥谷 道生, 山本 航大, 山田 啓貴, 岡野 隆一, 西村 啓佑, 上田 洋, 三枝 淳

  (一社)日本リウマチ学会, Mar. 2025, 日本リウマチ学会総会・学術集会プログラム・抄録集, 69回, 731 - 731, Japanese


• 関節リウマチ患者におけるメトトレキサート投与状況と関節リウマチの疾患活動性および治療薬剤費に与える影響の検討

  山本 航大, 白杉 郁, 山田 啓貴, 岡野 隆一, 西村 啓佑, 千藤 荘, 上田 洋, 三枝 淳

  (一社)日本リウマチ学会, Mar. 2025, 日本リウマチ学会総会・学術集会プログラム・抄録集, 69回, 862 - 862, Japanese


• 抗SS-A抗体陽性関節リウマチ患者におけるb/tsDMARDs継続率の検討-関西多施設ANSWERコホートを用いた検討-

  西坂一馬, 能瀬洋子, 山下真依, 白杉郁, 山田啓貴, 仲郁子, 岡野隆一, 西村啓佑, 上田洋, 千藤荘, 壷坂正徳, 亀長智幸, 中野直樹, 林申也, 山本渉, 大西輝, 村上孝作, 辻本考平, 勝島將夫, 橋本求, 吉川紋佳, 小谷卓矢, 安室秀樹, 孫瑛洙, 伊丹哲, 野崎祐史, 黒田良祐, 三枝淳

  2025, 日本リウマチ学会総会・学術集会プログラム・抄録集, 69th


• Assessing the Impact of Automated Transport Systems on Sample Processing Stability and Bioresource Quality

  KIM Jeong Hui, 佐藤伊都子, 勝亦柚衣, 森本耕平, 岡野隆一, 中村恵宣, 岡崎葉子, 今西孝充, 松岡広, 千藤荘

  2025, 医療検査と自動化(Web), 50(4) (4)


• Evaluation of the Collection and Distribution System for Residual Whole Blood Samples in a Hospital-Based Biobank

  勝亦柚衣, 金貞姫, 佐藤伊都子, 森本耕平, 岡野隆一, 中村恵宣, 岡崎葉子, 今西孝充, 千藤荘, 松岡広

  2025, 医療検査と自動化(Web), 50(4) (4)


• MPNスクリーニング検査でみつかるCALR E381Aについて

  立田彩葉, 松本久幸, 西川佳佑, 野口依子, 今西孝充, 千藤荘

  2025, 日臨技近畿支部医学検査学会(Web), 64th


• 脊髄性筋萎縮症(SMA)診断におけるデジタルPCR法導入の意義と課題

  吉免綾花, 野口依子, 松本久幸, 西川佳佑, 今西孝充, 千藤荘, 坊亮輔, 西尾久英

  2025, 日臨技近畿支部医学検査学会(Web), 64th


• 既存ECLIA法による唾液コルチゾール測定の実用性の検討

  小畠正樹, 大町侑香, 友藤清爾, 藤井研己, 石田奈美, 山本美野子, 辻本泰貴, 山本直希, 鈴木正暉, 浦井伸, 坂東弘教, 山本雅昭, 千藤荘, 小川渉, 福岡秀規

  2025, 臨床内分泌代謝Update抄録集(Web), 35th


• 樹状細胞および骨髄由来抑制細胞(MDSC)に対するJAK阻害薬6種の作用比較

  西坂一馬, 千藤荘, 山田啓貴, 岡野隆一, 西村啓佑, 上田洋, 三枝淳

  2025, 日本臨床免疫学会総会プログラム・抄録集, 53rd


• フェーズIIにおけるJAK阻害剤の適応-どのようなRA患者に使用すべきか-

  千藤荘

  2025, 九州リウマチ学会プログラム抄録集, 69th


• SLEの疾患活動性と臓器病変の評価におけるCLEIA法による抗dsDNA抗体の有用性の検討

  吉田 奈津希, 生戸 健一, 千藤 荘, 今西 孝充, 三枝 淳, 矢野 嘉彦

  (一社)日本臨床衛生検査技師会, May 2024, 日本医学検査学会抄録集, 73回, 37 - 37, Japanese


• SLEの患者報告アウトカム Lupus Patient-Reported Outcome tool(LupusPRO)のSLICC/ACR damage indexに対する予測的妥当性 LUNAレジストリ

  能瀬 洋子, 大西 輝, 西村 啓佑, 山本 譲, 山田 啓貴, 千藤 荘, 上田 洋, 佐田 憲映, 一瀬 邦弘, 吉見 竜介, 大野 滋, 矢嶋 宣幸, 梶山 浩, 佐藤 秀三, 下島 恭弘, 藤原 道雄, 木田 節, 宮脇 義亜, 松尾 祐介, 三枝 淳

  (一社)日本リウマチ学会, Mar. 2024, 日本リウマチ学会総会・学術集会プログラム・抄録集, 68回, 561 - 561, Japanese


• JAK阻害薬1 JAK阻害薬のcyclingにおける有効性の比較検討 関西多施設ANSWER cohortを用いた解析

  前田 俊恒, 林 申也, 中野 直樹, 亀長 智幸, 岡野 隆一, 白杉 郁, 神野 定男, 山本 譲, 上田 洋, 山田 啓貴, 西村 啓佑, 山下 真依, 千藤 荘, 山本 英里子, 山本 渉, 村田 浩一, 藤井 貴之, 秦 健一郎, 吉川 紋佳, 蛯名 耕介, 惠谷 悠紀, 吉田 直史, 安室 秀樹, 原 良太, 片山 昌紀, 橋本 求, 岡野 匡志, 壷坂 正徳

  (一社)日本リウマチ学会, Mar. 2024, 日本リウマチ学会総会・学術集会プログラム・抄録集, 68回, 564 - 564, Japanese


• 高齢関節リウマチ患者における寛解と低疾患活動性の比較検討 関西多施設共同研究ANSWERコホートを用いた検討

  山本 英里子, 神野 定男, 山田 啓貴, 山本 渉, 鬼澤 秀夫, 大西 輝, 平松 ゆり, 武内 徹, 沖田 康孝, 山下 真依, 能瀬 洋子, 白杉 郁, 岡野 隆一, 西村 啓佑, 上田 洋, 千藤 荘, 壷坂 正徳, 亀長 智幸, 中野 直樹, 前田 俊恒, 林 申也, 芦田 千聖, 野崎 祐史, 岡野 匡志, 橋本 求, 田中 晶大, 孫 瑛洙, 黒田 良祐, 三枝 淳

  (一社)日本リウマチ学会, Mar. 2024, 日本リウマチ学会総会・学術集会プログラム・抄録集, 68回, 855 - 855, Japanese


• 好酸球性多発血管炎性肉芽腫症(EGPA)による多発単神経炎に対する寛解導入療法中にくも膜下出血(SAH)を発症した一例

  安場 遥香, 山田 啓貴, 山岡 匠, 山本 航大, 山本 英里子, 西村 啓佑, 千藤 荘, 上田 洋, 三枝 淳

  (一社)日本リウマチ学会, Mar. 2024, 日本リウマチ学会総会・学術集会プログラム・抄録集, 68回, 885 - 885, Japanese


• SLEの患者報告アウトカム Lupus Patient-Reported Outcome tool(LupusPRO)のSLICC/ACR damage indexに対する予測的妥当性 LUNAレジストリ

  能瀬 洋子, 大西 輝, 西村 啓佑, 山本 譲, 山田 啓貴, 千藤 荘, 上田 洋, 佐田 憲映, 一瀬 邦弘, 吉見 竜介, 大野 滋, 矢嶋 宣幸, 梶山 浩, 佐藤 秀三, 下島 恭弘, 藤原 道雄, 木田 節, 宮脇 義亜, 松尾 祐介, 三枝 淳

  (一社)日本リウマチ学会, Mar. 2024, 日本リウマチ学会総会・学術集会プログラム・抄録集, 68回, 561 - 561, Japanese


• 当科おける膠原病性間質性肺炎に対するニンテダニブの安全性と有効性の検討

  山岡匠, 安場遥香, 山本航大, 山本英里子, 水川薫, 西坂一馬, 山下真依, 能瀬洋子, 市川晋也, 米田勝彦, 白杉郁, 山田啓貴, 西村啓佑, 千藤荘, 上田洋, 三枝淳

  2024, 日本リウマチ学会総会・学術集会プログラム・抄録集, 68th


• マイクロバイオームと免疫疾患 腸内細菌が産生するリノール酸代謝物と腸内細菌叢の異常はコラーゲン誘発性関節炎モデルマウスの疾患活動性と関連する

  米田 勝彦, 千藤 荘, 西村 啓佑, 上田 洋, 三枝 淳

  (一社)日本臨床免疫学会, Oct. 2023, 日本臨床免疫学会総会プログラム・抄録集, 51回, 77 - 77, Japanese


• 寛解導入治療開始後に多発動脈瘤および右胃大網動脈瘤破裂をきたした顕微鏡的多発血管炎の一例

  中川 大章, 長谷川 侑美, 片岡 渉, 相内 志津子, 水川 薫, 西坂 一馬, 千藤 荘, 山田 啓貴, 西村 啓佑, 上田 洋, 三枝 淳

  (一社)日本リウマチ学会, Mar. 2023, 日本リウマチ学会総会・学術集会プログラム・抄録集, 67回, 840 - 840, Japanese


• 持続型G-CSF製剤による薬剤性大型血管炎の1例

  水川 薫, 長谷川 侑美, 片岡 渉, 相内 志津子, 中川 大章, 西坂 一馬, 山田 啓貴, 西村 啓佑, 千藤 荘, 上田 洋, 三枝 淳

  (一社)日本リウマチ学会, Mar. 2023, 日本リウマチ学会総会・学術集会プログラム・抄録集, 67回, 891 - 891, Japanese


• Felty症候群による好中球減少に対してステロイド大量療法,メトトレキサート,アバタセプトが奏効した一例

  相内 志津子, 長谷川 侑美, 片岡 渉, 水川 薫, 中川 大章, 西坂 一馬, 山田 啓貴, 西村 啓佑, 千藤 荘, 上田 洋, 三枝 淳

  (一社)日本リウマチ学会, Mar. 2023, 日本リウマチ学会総会・学術集会プログラム・抄録集, 67回, 865 - 865, Japanese


• tsDMARDsとbDMARDsによる関節リウマチ患者の非炎症性疼痛へ及ぼす効果の比較~関西多施設共同研究ANSWER Cohortを用いた検討~

  山下真依, 岡野隆一, 白杉郁, 山田啓貴, 西村啓佑, 千藤荘, 上田洋, 前田俊恒, 林申也, 山本渉, 大西輝, 村上孝作, 斯波秀行, 秦健一郎, 辻本考平, 蛯名耕介, 孫瑛洙, 吉田直史, 吉田直史, 原良太, 渡部龍, 橋本求, 黒田良祐, 三枝淳

  2023, 日本リウマチ学会総会・学術集会プログラム・抄録集, 67th


• Neddylation制御による関節リウマチおよびリウマチ肺の新規治療法開発

  千藤荘

  2023, ひょうご科学技術協会研究成果報告書(Web), 2023


• ミコフェノール酸モフェチル併用が有効であったTAFRO症候群の一例

  長谷川侑美, 片岡渉, 相内志津子, 水川薫, 中川大章, 西坂一馬, 山下真依, 白杉郁, 千藤荘, 山田啓貴, 西村啓佑, 上田洋, 三枝淳

  2023, 日本リウマチ学会総会・学術集会プログラム・抄録集, 67th


• バリシチニブが奏功したマクロファージ活性化症候群を伴う成人スチル病の1例

  西坂一馬, 片岡渉, 長谷川侑美, 相内志津子, 水川薫, 中川大章, 永本匠, 山田啓貴, 西村啓佑, 千藤荘, 上田洋, 三枝淳

  2023, 日本リウマチ学会総会・学術集会プログラム・抄録集, 67th


• Resolvin D5 Modulates Th17/Treg Cell Differentiation and Suppresses Osteoclastogenesis

  Hirotaka Yamada, Jun Saegusa, Sho Sendo, Yo Ueda, Takaichi Okano, Yoshikazu Fujikawa, Yuzuru Yamamoto, Takumi Nagamoto, Yoshihide Ichise, Ikuko Naka, Kengo Akashi, Akira Onishi, Masakazu Shinohara, Akio Morinobu

  Oct. 2020, ARTHRITIS & RHEUMATOLOGY, 72, English

  Summary international conference


• Combined Inhibition of Autophagy and Glutamine Metabolism Suppresses Cell Growth of RA Synoviocytes and Ameliorates Arthritis in SKG Mice

  Ikuko Naka, Jun Saegusa, Kenichi Uto, Yuzuru Yamamoto, Yoshihide Ichise, Hirotaka Yamada, Yo Ueda, Takaichi Okano, Soshi Takahashi, Sho Sendo, Akio Morinobu

  Oct. 2020, ARTHRITIS & RHEUMATOLOGY, 72, English

  Summary international conference


• 関節リウマチの治療評価と予測 Adalimumab寛解中止後の関節リウマチ症例における"BMI非Normal"の再燃リスクとしての可能性について

  吉川 卓宏, 松井 聖, 岡野 匡志, 真本 建司, 杉岡 優子, 多田 昌弘, 和田 誠, 原 良太, 千藤 荘, 岡野 隆一, 一瀬 良英, 仲 郁子, 兪 炳碩, 中林 晃彦, 松浦 良信, 金山 康秀

  (一社)日本リウマチ学会, Aug. 2020, 日本リウマチ学会総会・学術集会プログラム・抄録集, 64回, 455 - 455, Japanese


• The Comparative Efficacy of Pneumocystis Pneumonia Prophylactic Regimens in Patients with Connective Tissue Diseases Receiving Prolonged High-dose Glucocorticoids

  Kengo Akashi, Sadao Jinno, Akira Onishi, Mai Yamashita, Yoko Nose, Takaichi Okano, Yo Ueda, Sho Sendo, Jun Saegusa, Akio Morinobu

  Oct. 2019, ARTHRITIS & RHEUMATOLOGY, 71, English

  Summary international conference


• ベーチェット病に伴う仙腸関節炎に対して抗TNFα阻害薬で治療中に、食道穿通病変と回盲部潰瘍が出現し、内科的治療で治療しえた腸管型ベーチェット病の1例

  能瀬 洋子, 井上 綾華, 上田 洋, 宮崎 はる香, 大井 充, 岡野 隆一, 千藤 荘, 明石 健吾, 大西 輝, 星 奈美子, 三枝 淳, 児玉 裕三, 森信 暁雄

  (一社)日本臨床免疫学会, Oct. 2019, 日本臨床免疫学会総会プログラム・抄録集, 47回, 112 - 112, Japanese


• PREDICTION OF RECURRENCE AFTER DISCONTINUATION OF ADALIMUMAB BY USING ULTRASOUND ASSESSMENT -THE PROUD STUDY-

  Tadashi Okano, Ryota Hara, Makoto Wada, Tatsuya Koike, Kenji Mamoto, Yuko Sugioka, Masahiro Tada, Takanori Fujimura, Sho Sendo, Takaichi Okano, Yoshihide Ichise, Ikuko Naka, Heiseki Yu, Akihiko Nakabayashi, Yoshinobu Matsuura, Takahiro Yoshikawa, Masao Tamura, Masayasu Kitano, Yasuhide Kanayama

  Jun. 2019, ANNALS OF THE RHEUMATIC DISEASES, 78, 1659 - 1659, English

  Summary international conference


• THE CLINICAL FEATURES OF ANTI-TIF1GAMMA ANTIBODY POSITIVE DERMATOMYOSITIS

  Yoshikazu Fujikawa, Kengo Akashi, Motoko Katayama, Mai Yamashita, Yoko Nose, Takaichi Okano, Yo Ueda, Sho Sendo, Akira Onishi, Jun Saegusa, Akio Morinobu

  Jun. 2019, ANNALS OF THE RHEUMATIC DISEASES, 78, 1559 - 1559, English

  Summary international conference


• 関節リウマチにおける赤血球中ポリグルタミル化メトトレキサート測定の意義

  高橋 未帆, 西田 美和, 辻 剛, 上村 裕子, 森 あやの, 柴田 美帆, 齋藤 敏晴, 千藤 荘, 篠原 正和, 熊谷 俊一

  一定量のメトトレキサート(MTX)を長期間服用している関節リウマチ(RA)患者234名(男性42名、女性192名)を対象に、赤血球中の各ポリグルタミル化メトトレキサート(MTXPG)濃度を測定し、疾患活動性や肝機能障害との関連について検討した。DAS28(CRP)はMTXPG1、MTXPG2、MTXPG3、MTXPG4と総MTXPGのいずれとも有意の相関は認められなかった。総MTXPG濃度はMTX内服量の増加に伴い有意に上昇し、MTXPG2、MTXPG3、MTXPG4濃度もMTX投与量とは強い正相関を認めたが、MTXPG1濃度との相関は弱かった。また、総MTXPG、MTXPG1、MTXPG2、MTXPG3、MTXPG4すべての濃度がASTおよびALTと有意の正相関を認め、総MTXPGのカットオフ濃度は100.0nmol/L、MTXPG1は37.9nmol/L、MTXPG2は30.5nmol/L、MTXPG3は22.1nmol/L、MTXPG4は3.4nmol/Lであり、総MIXPG濃度および各MTXPG濃度はASTやALTが80U/Lという比較的高値の肝障害の指標となる可能性が示唆された。80U/L以上群では80U/L未満群に比べ、総MTXPG、MTXPG2、MTXPG3、MTXPG4濃度が有意に高値であった。

  (一社)日本臨床検査医学会, May 2019, 臨床病理, 67(5) (5), 433 - 442, Japanese


• リウマチ性疾患の超音波検査 関節エコーを用いたアダリムマブ寛解休薬後の再燃予測についての多施設前向き研究 PROUD study

  岡野 匡志, 真本 建司, 小池 達也, 杉岡 優子, 多田 昌弘, 和田 誠, 原 良太, 藤村 貴則, 千藤 荘, 岡野 隆一, 一瀬 良英, 仲 郁子, 兪 炳碩, 中林 晃彦, 松浦 良信, 吉川 卓宏, 田村 誠朗, 北野 将康, 金山 康秀

  (一社)日本リウマチ学会, Mar. 2019, 日本リウマチ学会総会・学術集会プログラム・抄録集, 63回, 428 - 428, Japanese


• アダリムマブの寛解後休薬についての検討

  千藤 荘, 藤川 良一, 永本 匠, 山本 譲, 一瀬 良英, 山田 啓貴, 仲 郁子, 上田 洋, 岡野 隆一, 明石 健吾, 大西 輝, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2019, 日本リウマチ学会総会・学術集会プログラム・抄録集, 63回, 623 - 623, Japanese


• 当施設におけるニューモシスティス肺炎に対する治療の実態

  明石 健吾, 神野 定男, 片山 素子, 山下 真依, 能瀬 洋子, 藤川 良一, 永本 匠, 山本 譲, 山田 啓貴, 一瀬 良英, 仲 郁子, 岡野 隆一, 上田 洋, 千藤 荘, 大西 輝, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2019, 日本リウマチ学会総会・学術集会プログラム・抄録集, 63回, 729 - 729, Japanese


• SLEとの鑑別を要した自己免疫性溶血性貧血と特発性膜性腎症の合併例

  片山 素子, 千藤 荘, 山下 真依, 能瀬 洋子, 岡野 隆一, 上田 洋, 明石 健吾, 大西 輝, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2019, 日本リウマチ学会総会・学術集会プログラム・抄録集, 63回, 735 - 735, Japanese


• 関節リウマチとSLEを合併した強皮症オーバーラップ症候群の一例

  山下 真依, 岡野 隆一, 能瀬 洋子, 上田 洋, 千藤 荘, 明石 健吾, 大西 輝, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2019, 日本リウマチ学会総会・学術集会プログラム・抄録集, 63回, 758 - 758, Japanese


• 抗TIF1γ抗体陽性皮膚筋炎症例の臨床的特徴

  藤川 良一, 明石 健吾, 片山 素子, 山下 真依, 能瀬 洋子, 永本 匠, 山本 譲, 山田 啓貴, 一瀬 良英, 仲 郁子, 岡野 隆一, 上田 洋, 千藤 荘, 大西 輝, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2019, 日本リウマチ学会総会・学術集会プログラム・抄録集, 63回, 767 - 767, Japanese


• ANCA関連血管炎の寛解導入療法中に、リツキシマブに起因する急性血小板減少が疑われた3例

  能瀬 洋子, 上田 洋, 片山 素子, 山下 真依, 岡野 隆一, 千藤 荘, 明石 健吾, 大西 輝, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2019, 日本リウマチ学会総会・学術集会プログラム・抄録集, 63回, 784 - 784, Japanese


• 顔面から頸部の表在感覚障害をきたしたIgA血管炎の1例

  千藤 荘, 三枝 淳, 上田 洋, 岡野 隆一, 明石 健吾, 森信 暁雄

  (一社)日本臨床免疫学会, Nov. 2018, 日本臨床免疫学会総会プログラム・抄録集, 46回, 110 - 110, Japanese


• トファシチニブは骨髄由来抑制性細胞(MDSC)の増殖を促しSKGマウスの間質性肺炎を抑制する

  千藤 荘, 三枝 淳, 山田 啓貴, 上田 洋, 森信 暁雄

  (一社)日本臨床免疫学会, Nov. 2018, 日本臨床免疫学会総会プログラム・抄録集, 46回, 85 - 85, Japanese


• トファシチニブは骨髄由来抑制性細胞(MDSC)の増殖を促しSKGマウスの間質性肺炎を抑制する

  千藤 荘, 三枝 淳, 山田 啓貴, 上田 洋, 森信 暁雄

  (一社)日本臨床免疫学会, Nov. 2018, 日本臨床免疫学会総会プログラム・抄録集, 46回, 124 - 124, Japanese


• 顔面から頸部の表在感覚障害をきたしたIgA血管炎の1例

  千藤 荘, 三枝 淳, 上田 洋, 岡野 隆一, 明石 健吾, 森信 暁雄

  (一社)日本臨床免疫学会, Nov. 2018, 日本臨床免疫学会総会プログラム・抄録集, 46回, 83 - 83, Japanese


• サイトメガロウイルス食道炎・胃炎による門脈ガス血症を来した多発血管炎性肉芽腫症

  森 直樹, 千藤 荘, 片山 素子, 寺田 菜々子, 能瀬 洋子, 山下 真依, 岡野 隆一, 上田 洋, 明石 健吾, 大西 輝, 三枝 淳, 森信 暁雄

  (一社)日本臨床免疫学会, Nov. 2018, 日本臨床免疫学会総会プログラム・抄録集, 46回, 138 - 138, Japanese


• 関節リウマチにおける赤血球中ポリグルタミル化メトトレキサートの継時的変化と臨床的効果との関連性

  高橋 未帆, 西田 美和, 柴田 美帆, 森 あやの, 齋藤 敏晴, 納田 安啓, 米田 勝彦, 高橋 宗史, 籏智 さおり, 千藤 荘, 辻 剛, 熊谷 俊一

  (一社)日本臨床検査医学会, Oct. 2018, 臨床病理, 66(補冊) (補冊), 136 - 136, Japanese


• 感染症 RA患者の疾患活動性に対するtrimethoprim-sulfamethoxazoleの効果 ANSWER縦断的コホート研究(Infection The effects of trimethoprim-sulfamethoxazole on disease activity in patients with RA: ANSWER longitudinal cohort study)

  Onishi Akira, Akashi Kengo, Hashimoto Motomu, Yamamoto Wataru, Murata Koichi, Katayama Masaki, Amuro Hideki, Son Yonsu, Yoshida Shuzo, Nagai Koji, Hara Ryota, Ebina Kosuke, Hirano Toru, Yamamoto Yuzuru, Yamada Hirotaka, Ichise Yoshihide, Naka Ikuko, Okano Takaichi, Takahashi Soshi, Ueda Yo, Sendo Sho, Saegusa Jun, Morinobu Akio

  (一社)日本リウマチ学会, Mar. 2018, 日本リウマチ学会総会・学術集会プログラム・抄録集, 62回, 415 - 415, English

  [Refereed]


• 関節リウマチ治療におけるニューモシスティス肺炎予防の実態 関西多施設共同研究ANSWERコホートデータから

  明石 健吾, 大西 輝, 永井 孝治, 吉田 周造, 山本 渉, 橋本 求, 村田 浩一, 孫 瑛洙, 安室 秀樹, 原 良太, 平野 亨, 蛯名 耕介, 片山 昌紀, 千藤 荘, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2018, 日本リウマチ学会総会・学術集会プログラム・抄録集, 62回, 767 - 767, Japanese


• 仙腸関節炎に対してTNFα阻害薬で加療中に消化管穿孔で顕在化した腸管型ベーチェット病の一例

  大木 洋子, 千藤 荘, 白井 太一朗, 藤川 良一, 永本 匠, 岡野 隆一, 高橋 宗史, 明石 健吾, 大西 輝, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2018, 日本リウマチ学会総会・学術集会プログラム・抄録集, 62回, 760 - 760, Japanese


• 関節リウマチの治療評価と予測1 血清メタボローム解析による関節リウマチ患者の生物学的製剤治療反応性の予測バイオマーカーの同定

  高橋 宗史, 三枝 淳, 大木 洋子, 白井 太一朗, 藤川 良一, 永本 匠, 山本 譲, 山田 啓貴, 一瀬 良英, 仲 郁子, 岡野 隆一, 明石 健吾, 上田 洋, 千藤 荘, 大西 輝, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2018, 日本リウマチ学会総会・学術集会プログラム・抄録集, 62回, 517 - 517, Japanese


• 血管炎5:大型血管炎症例集積研究 高安動脈炎における当院での治療成績とトシリズマブの有効性についての検討

  藤川 良一, 千藤 荘, 大木 洋子, 白井 太一朗, 永本 匠, 山本 譲, 山田 啓貴, 一瀬 良英, 仲 郁子, 岡野 隆一, 高橋 宗史, 上田 洋, 明石 健吾, 大西 輝, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2018, 日本リウマチ学会総会・学術集会プログラム・抄録集, 62回, 525 - 525, Japanese


• 多発微小肝動脈瘤を伴った顕微鏡学的多発血管炎の一例

  白井 太一朗, 岡野 隆一, 大木 洋子, 藤川 良一, 永本 匠, 高橋 宗史, 千藤 荘, 明石 健吾, 大西 輝, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2018, 日本リウマチ学会総会・学術集会プログラム・抄録集, 62回, 824 - 824, Japanese


• 多発性筋炎・皮膚筋炎3 抗MDA5抗体陽性間質性肺疾患の長期臨床経過

  明石 健吾, 大木 洋子, 白井 太一朗, 藤川 良一, 永本 匠, 岡野 隆一, 高橋 宗史, 千藤 荘, 大西 輝, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2018, 日本リウマチ学会総会・学術集会プログラム・抄録集, 62回, 492 - 492, Japanese


• Myeloid-derived suppressor cells in non-neoplastic inflamed organs.

  Sho Sendo, Jun Saegusa, Akio Morinobu

  Background: Myeloid-derived suppressor cells (MDSCs) are a highly heterogeneous population of immature myeloid cells with immunosuppressive function. Although their function in tumor-bearing conditions is well studied, less is known about the role of MDSCs in various organs under non-neoplastic inflammatory conditions. Main body: MDSCs are divided into two subpopulations, G-MDSCs and M-MDSCs, and their distribution varies between organs. MDSCs negatively control inflammation in inflamed organs such as the lungs, joints, liver, kidneys, intestines, central nervous system (CNS), and eyes by suppressing T cells and myeloid cells. MDSCs also regulate fibrosis in the lungs, liver, and kidneys and help repair CNS injuries. MDSCs in organs are plastic and can differentiate into osteoclasts and tolerogenic dendritic cells according to the microenvironment under non-neoplastic inflammatory conditions. Conclusion: This article summarizes recent findings about MDSCs under inflammatory conditions, especially with respect to their function and differentiation in specific organs.

  2018, Inflammation and regeneration, 38(19) (19), 19 - 19, English, International magazine

  [Refereed]


• CD11b(+)Gr1(dim) tolerogenic dendritic dell-like cells are expanded in interstitial lung disease in SKG mice

  Sho Sendo, Jun Saegusa, Hirotaka Yamada, Yoshihide Ichise, Ikuko Naka, Takaichi Okano, Soshi Takahashi, Yo Ueda, Kengo Akashi, Akio Morinobu

  Dec. 2017, CYTOKINE, 100, 125 - 125, English

  Summary international conference


• CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice

  Sho Sendo, Jun Saegusa, Hirotaka Yamada, Yoshihide Ichise, Ikuko Naka, Yo Ueda, Takaichi Okano, Soshi Takahashi, Kengo Akashi, Akira Onishi, Akio Morinobu

  Oct. 2017, ARTHRITIS & RHEUMATOLOGY, 69, English

  Summary international conference


• Inhibition of the Mechanistic Target of Rapamycin Pathway and Glutaminolysis Facilitates the Expansion of Myeloid-Derived Suppressor Cells and Synergistically Ameliorates Arthritis in SKG Mice

  Yo Ueda, Takaichi Okano, Hirotaka Yamada, Yoshihide Ichise, Ikuko Naka, Soshi Takahashi, Sho Sendo, Kengo Akashi, Akira Onishi, Jun Saegusa, Akio Morinobu

  Oct. 2017, ARTHRITIS & RHEUMATOLOGY, 69, English

  Summary international conference


• シェーグレン症候群による亜急性感覚失調性ニューロパチーの1例

  岡野 隆一, 明石 健吾, 白井 太一朗, 大木 洋子, 永本 匠, 藤川 良一, 高橋 宗史, 千藤 荘, 大西 輝, 三枝 淳, 森信 暁雄

  【症例】57歳女性．4か月前から左大腿部および左足先のぴりぴりした異常感覚が出現し，3か月前に異常感覚が左半身に広がった．2か月前から左上下肢の運動障害が出現し，近医受診後当科紹介となった．神経学的所見では左対光反射の減弱，四肢～体幹の全感覚低下（位置覚，振動覚，触覚）および，四肢の腱反射消失を認めた．NCSでは運動神経はほぼ正常であったが，感覚神経は電位導出不能であり，pure sensory neuropathy（SAN）の所見であった．頸椎MRIでC2-4レベルの後索にT2 highな病変を認め，腰椎MRIでTh10レベルの後索にT2 highかつ造影効果を認める病変があり，後根神経節の障害が推察された．神経障害の原因として，抗SSA抗体陽性，シルマーテスト5 mm/3 mmと低下を認めたことから，シェーグレン症候群（SS）にともなうSANであると診断され，ステロイドおよび免疫抑制療法を施行された．【考察】SSによる神経障害の大部分はsmall fiber neuropathyだが，神経障害の5％と頻度は高くないもののSANを引き起こすこともある．SANは重篤な後遺症を残すこともおおい予後不良疾患である．今回我々は亜急性に失調症状が進行したprimary SSに伴うSANを経験したので文献的考察を加えここに報告する．

  (一社)日本臨床免疫学会, Aug. 2017, 日本臨床免疫学会会誌, 40(4) (4), 305 - 305, Japanese


• Tacrolimusで初めて治療し得た心筋障害合併例を含むTAFRO症候群の2症例

  白井 太一朗, 脇 大輔, 千藤 荘, 明石 健吾, 大西 輝, 三枝 淳, 森信 暁雄

  【背景】TAFRO症候群はmulticentric Castleman's disease（MCD）の亜型とされ，血小板減少症，腔水症，骨髄線維症等を特徴とした稀な炎症性疾患である．MCD同様Interleukin（IL）-6がkey cytokineとされたが，血小板減少等はIL-6作用と矛盾し，Tocilizumab（TCZ）の奏効率はMCDに比して低い．既報でCyclosporineの有用性が示唆され，我々は心筋障害合併例を含む2症例に初めてTacrolimus（TAC）で治療を行った．【症例1】68歳女性．発熱，血小板減少，胸腹水，骨髄線維症とリンパ節生検でTAFRO症候群と診断した．Glucocorticoids（GC）単剤では症状改善乏しく，TCZを開始したが効果なく，膿胸に伴う敗血症を来した．TACへ変更したところ速やかに寛解に至った．【症例2】17歳男性．発熱，血小板減少，胸腹水の精査中，急性に瀰漫性心筋障害を伴う重症心不全を来した．TAFRO症候群に伴う心筋障害と診断し，GCとTACで治療開始したところ心筋障害は速やかに可逆的に改善し寛解に至った．【考察】Literature reviewから，TAFRO症候群でのTCZの奏効率は50％以下で，GCとTCZの併用療法は感染症合併率が高かった．TAFRO症候群とIL-2，IFN-γ induced protein 10（IP-10）等のTh1 cytokinesの関係が示唆され，心筋障害への関与も想定されることから，Th1 cytokinesを抑制するTACは有望な治療薬と考えられる．本症例はTACが心筋障害合併例を含むTAFRO症候群に有効かつ安全に使用できることを示す初めての報告である．

  (一社)日本臨床免疫学会, Aug. 2017, 日本臨床免疫学会会誌, 40(4) (4), 307 - 307, Japanese


• 炎症性筋疾患に合併する間質性肺疾患における血清マーカーの推移

  明石 健吾, 大木 洋子, 白井 太一朗, 藤川 良一, 永本 匠, 山本 譲, 山田 啓貴, 一瀬 良英, 仲 郁子, 岡野 隆一, 高橋 宗史, 上田 洋, 千藤 荘, 大西 輝, 三枝 淳, 森信 暁雄

  (一社)日本臨床免疫学会, Aug. 2017, 日本臨床免疫学会会誌, 40(4) (4), 308 - 308, Japanese


• GLUTAMINE METABOLISM PLAYS A KEY ROLE IN THE CELL GROWTH OF FIBROBLAST-LIKE SYNOVIOCYTES IN RHEUMATOID ARTHRITIS

  S. Takahashi, J. Saegusa, H. Yamada, Y. Ichise, I. Naka, T. Okano, K. Akashi, S. Sendo, Y. Ueda, A. Onishi, A. Morinobu

  Jun. 2017, ANNALS OF THE RHEUMATIC DISEASES, 76, 487 - 488, English

  Summary international conference


• THE EFFICACY OF 2-YEARS DENOSUMAB TREATMENT FOR GLUCOCORTICOID-INDUCED OSTEOPOROSIS (GIOP)

  K. Akashi, K. Nishimura, G. Kageyama, S. Ichikawa, T. Shirai, Y. Yamamoto, Y. Ichise, H. Yamada, I. Naka, D. Waki, T. Okano, S. Takahashi, Y. Ueda, S. Sendo, A. Onishi, J. Saegusa, A. Morinobu

  Jun. 2017, ANNALS OF THE RHEUMATIC DISEASES, 76, 699 - 699, English

  Summary international conference


• CD11B(+)GR1DIM TOLEROGENIC DENDRITIC CELL-LIKE CELLS ARE EXPANDED IN INTERSTITIAL LUNG DISEASE IN SKG MICE

  S. Sendo, J. Saegusa, Y. Ichise, H. Yamada, I. Naka, T. Okano, S. Takahashi, Y. Ueda, K. Akashi, A. Onishi, A. Morinobu

  Jun. 2017, ANNALS OF THE RHEUMATIC DISEASES, 76, 507 - 508, English

  Summary international conference


• 骨粗鬆症と骨代謝/変形性関節症・軟骨 ステロイド骨粗鬆症(GIO)に対するデノスマブの有効性 2年間の使用成績

  明石 健吾, 西村 啓佑, 蔭山 豪一, 市川 晋也, 白井 太一朗, 山本 譲, 一瀬 良英, 山田 啓貴, 仲 郁子, 津田 耕作, 脇 大輔, 岡野 隆一, 高橋 宗史, 上田 洋, 千藤 荘, 大西 輝, 古形 芳則, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2017, 日本リウマチ学会総会・学術集会プログラム・抄録集, 61回, 545 - 545, Japanese


• シクロスポリンが奏功した自己免疫性好中球減少症を伴う乾癬性関節炎の一例

  白井 太一朗, 脇 大輔, 千藤 荘, 市川 晋也, 山本 譲, 明石 健吾, 大西 輝, 古形 芳則, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2017, 日本リウマチ学会総会・学術集会プログラム・抄録集, 61回, 699 - 699, Japanese


• 致死的経過を辿ったRheumatoid Vasculitisに伴う肺動脈性肺高血圧症の一例

  市川 晋也, 明石 健吾, 千藤 荘, 白井 太一朗, 山本 譲, 脇 大輔, 大西 輝, 古形 芳則, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2017, 日本リウマチ学会総会・学術集会プログラム・抄録集, 61回, 722 - 722, Japanese


• Glutamine Metabolism Plays a Crucial Role in the Pathogenesis of Rheumatoid Arthritis

  Soshi Takahashi, Jun Saegusa, Ikuko Naka, Kosaku Tsuda, Takaichi Okano, Kengo Akashi, Sho Sendo, Yo Ueda, Akira Onishi, Yoshinori Kogata, Akio Morinobu

  Oct. 2016, ARTHRITIS & RHEUMATOLOGY, 68, English

  Summary international conference


• Dual Effect of 3-Bromopyruvate on Both Th17 and Treg Cell Differentiation and Dendritic Cell Activation Ameliorates Autoimmune Arthritis in Mice

  Takaichi Okano, Jun Saegusa, Keisuke Nishimura, Yo Ueda, Sho Sendo, Soshi Takahashi, Kengo Akashi, Akira Onishi, Akio Morinobu

  Oct. 2016, ARTHRITIS & RHEUMATOLOGY, 68, English

  Summary international conference


• CD11b+Gr1dimcells, Which Are Induced By GM-CSF Produced By Th17 and Group3 Innate Lymphoid Cell, May Facilitate the Progression of Pneumonitis in SKG Mice

  Sho Sendo, Jun Saegusa, Takaichi Okano, Soshi Takahashi, Akio Morinobu

  Oct. 2016, ARTHRITIS & RHEUMATOLOGY, 68, English

  Summary international conference


• Impact of Socioeconomic Status on Disease Outcomes in Japanese Patients with Rheumatoid Arthritis Under the Japanese National Insurance System

  Akira Onishi, Goichi Kageyama, Yo Ueda, Ikuko Naka, Kosaku Tsuda, Takaichi Okano, Soshi Takahashi, Kengo Akashi, Sho Sendo, Yoshinori Kogata, Jun Saegusa, Akio Morinobu

  Oct. 2016, ARTHRITIS & RHEUMATOLOGY, 68, English

  Summary international conference


• 関節リウマチ治療の効果判定における血清IL-6、CXCL13、MMP-3測定の有用性

  上村 裕子, 林 秀敏, 齋藤 敏晴, 梅田 良祐, 牟田 愛, 阿部 京介, 泉 真祐子, 千藤 荘, 辻 剛, 熊谷 俊一

  (一社)日本臨床検査医学会, Sep. 2016, 臨床病理, 64(補冊) (補冊), 10 - 13, Japanese


• 解糖系代謝阻害剤3-ブロモピルビン酸はマウス関節炎を抑制する

  岡野 隆一, 三枝 淳, 西村 啓介, 明石 健吾, 西田 美和, 高橋 宗史, 千藤 荘, 上田 洋, 大西 輝, 古形 芳則, 森信 暁雄

  (一社)日本臨床免疫学会, Aug. 2016, 日本臨床免疫学会会誌, 39(4) (4), 376 - 376, Japanese


• 3-BROMOPYRUVATE AMELIORATES AUTOIMMUNE ARTHRITIS BY EXERTING A DUAL EFFECT ON BOTH TH17 AND TREG CELL DIFFERENTIATION AND DENDRITIC CELL ACTIVATION

  T. Okano, J. Saegusa, K. Nishimura, S. Takahashi, S. Sendo, Y. Ueda, A. Onishi, A. Morinobu

  Jun. 2016, ANNALS OF THE RHEUMATIC DISEASES, 75, 113 - 113, English

  Summary international conference


• SOME OF THE PAINFUL RA PATIENTS UNDERRATE GLOBAL HEALTH VAS AT HOSPITALS

  G. Kageyama, A. Onishi, Y. Ueda, Y. Kamei, H. Yamada, Y. Ichise, D. Waki, I. Naka, K. Tsuda, T. Okano, S. Takahashi, M. Nishida, K. Akashi, K. Nishimura, S. Sendo, Y. Kogata, J. Saegusa, A. Morinobu

  Jun. 2016, ANNALS OF THE RHEUMATIC DISEASES, 75, 963 - 963, English

  Summary international conference


• SUBJECTIVE WELL-BEING OF JAPANESE RA PATIENTS WHO REACH TREATMENT TARGET IS HIGHER THAN THE JAPANESE AVERAGE

  G. Kageyama, A. Onishi, Y. Ueda, Y. Kamei, H. Yamada, Y. Ichise, D. Waki, I. Naka, K. Tsuda, T. Okano, S. Takahashi, M. Nishida, K. Akashi, K. Nishimura, S. Sendo, Y. Kogata, J. Saegusa, A. Morinobu

  Jun. 2016, ANNALS OF THE RHEUMATIC DISEASES, 75, 413 - 414, English

  Summary international conference


• KNOCKOUT OF ENDOTHELIN TYPE B RECEPTOR SIGNALING ATTENUATES BLEOMYCIN-INDUCED SKIN SCLEROSIS IN MICE

  K. Akashi, J. Saegusa, S. Sendo, K. Nishimura, K. Tsuda, I. Naka, T. Okano, S. Takahashi, M. Nishida, Y. Ueda, A. Morinobu

  Jun. 2016, ANNALS OF THE RHEUMATIC DISEASES, 75, 170 - 170, English

  Summary international conference


• ベーチェット病 特殊型ベーチェット病に対するTNF阻害剤の有効性

  西村 啓佑, 津田 耕作, 仲 郁子, 岡野 隆一, 明石 健吾, 高橋 宗史, 西田 美和, 上田 洋, 千藤 荘, 大西 輝, 古形 芳則, 蔭山 豪一, 三枝 淳, 河野 誠司, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2016, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回, 361 - 361, Japanese


• 関節リウマチの治療評価と予測 疼痛評価VASが高い患者の健康状態全般評価VASは過小申告されていることがある(ROCKoコホート研究から)

  蔭山 豪一, 大西 輝, 上田 洋, 仲 郁子, 津田 耕作, 岡野 隆一, 高橋 宗史, 西田 美和, 明石 健吾, 西村 啓佑, 千藤 荘, 古形 芳則, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2016, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回, 447 - 447, Japanese


• 関節リウマチの治療 QOL 治療目標に到達した関節リウマチ患者の主観的幸福度は、一般的な日本人より高い(ROCKoコホート研究から)

  蔭山 豪一, 大西 輝, 上田 洋, 仲 郁子, 津田 耕作, 岡野 隆一, 高橋 宗史, 西田 美和, 明石 健吾, 西村 啓佑, 千藤 荘, 古形 芳則, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2016, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回, 456 - 456, Japanese


• リウマチ性疾患の疫学 関節リウマチ患者における社会経済的要因が疾患活動性、日常生活動作に与える影響の検討(ROCKoコホート研究から)

  大西 輝, 蔭山 豪一, 上田 洋, 津田 耕作, 仲 郁子, 岡野 隆一, 明石 健吾, 西村 啓佑, 高橋 宗史, 西田 美和, 千藤 荘, 古形 芳則, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2016, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回, 468 - 468, Japanese


• メトトレキサート肝障害予測遺伝子モデルを基礎にした有効性予測モデル作成

  牟田 愛, 辻 剛, 梅田 良祐, 納田 安啓, 米田 勝彦, 阿部 京介, 泉 真祐子, 河野 泰秀, 千藤 荘, 籏智 さおり, 中澤 隆, 三崎 健太, 大西 輝, 上村 裕子, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2016, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回, 553 - 553, Japanese


• リウマチ性疾患の基礎研究 SKGマウス肺病変の進展に伴って増加するCD11b+Gr1dim cellはGM-CSFによって誘導される

  千藤 荘, 仲 郁子, 津田 耕作, 岡野 隆一, 西田 美和, 明石 健吾, 高橋 宗史, 上田 洋, 西村 啓佑, 大西 輝, 古形 芳則, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2016, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回(4) (4), 344 - 344, Japanese


• 生物学的製剤使用RA患者における血清MMP-3レベルの経時的変化と有効性との関連

  上村 裕子, 辻 剛, 梅田 良祐, 牟田 愛, 阿部 京介, 泉 真祐子, 河野 泰秀, 千藤 荘, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2016, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回, 514 - 514, Japanese


• Taurine As a Biomarker for Prediction of Response to Biologic Therapy in Rheumatoid Arthritis

  Soshi Takahashi, Jun Saegusa, Ikuko Naka, Kosaku Tsuda, Takaichi Okano, Kengo Akashi, Miwa Nishida, Keisuke Nishimura, Sho Sendo, Yo Ueda, Akira Onishi, Yoshinori Kogata, Goichi Kageyama, Akio Morinobu

  Oct. 2015, ARTHRITIS & RHEUMATOLOGY, 67, English

  Summary international conference


• High Serum IgG4 Concentration Is a Risk Factor for Relapse in IgG4-Related Disease

  Sho Sendo, Jun Saegusa, Akira Onishi, Ikuko Naka, Kosaku Tsuda, Takaichi Okano, Kengo Akashi, Soshi Takahashi, Miwa Nishida, Keisuke Nishimura, Yo Ueda, Yoshinori Kogata, Goichi Kageyama, Goh Tsuji, Shunichi Kumagai, Akio Morinobu

  Oct. 2015, ARTHRITIS & RHEUMATOLOGY, 67, English

  Summary international conference


• リウマチ性多発筋痛症におけるMMP-3測定の診断と治療についての検討

  上村 裕子, 林 秀敏, 高橋 敏夫, 齋藤 敏晴, 梅田 良祐, 牟田 愛, 千藤 荘, 辻 剛, 熊谷 俊一

  (一社)日本臨床検査医学会, Oct. 2015, 臨床病理, 63(補冊) (補冊), 096 - 096, Japanese


• [Not Available].

  津田 耕作, 明石 健吾, 西村 啓佑, 千藤 荘, 三枝 淳, 森信 暁雄

  【目的】シェーグレン症候群（SS）は主に外分泌腺を障害するが，基本的には全身性の自己免疫疾患であり，腺外症状として各種臓器障害を呈する．その中でSSの患者では疲労感の訴えはよく経験され，睡眠障害がその一因と考えられている．しかしSSの睡眠障害に関する報告は限定的である．そこで当科外来通院中の原発性SS患者における主観的睡眠観の評価およびそれに影響する因子の検討を行った．【方法】当科に通院中のpSS患者でステロイド内服しているものを除いた37人（全例女性）を対象とした．それぞれにピッツバーグ睡眠質問票（PSQI）および，シェーグレンの自覚症状質問票（ESPRI），うつ症状の質問票（PHQ-9），睡眠時無呼吸症のスクリーニング質問票（ESS）を実施し検討を行った．【結果】一般人口に比べて明らかに高い睡眠障害の有病率70％を有していた．また睡眠障害の程度は統計学的に有意にうつ症状の程度とBMIに関連を認め，特にうつの程度が最も影響を与えていた．【結論】pSSの患者では睡眠障害に注意し，うつ病等の精神疾患を含めたマネージメントを考えることで，QOLの改善につながるかもしれない．

  The Japan Society for Clinical Immunology, Sep. 2015, Japanese Journal of Clinical Immunology, 38(4) (4), 350 - 350, Japanese


• [Not Available].

  千藤 荘, 津田 耕作, 明石 健吾, 西村 啓佑, 三枝 淳, 森信 暁雄

  【目的】当科で経験した脊椎関節炎の臨床的特徴について検討する．【方法】2013年4月から2014年11月の間に当科に通院歴のある脊椎関節炎（SpA）患者57例を後ろ向きに検討した．【結果】57例の内訳としては，強直性脊椎炎（AS）10例，乾癬性関節炎（PsA）26例，掌蹠膿疱症性骨関節円（PAO）9例，炎症性腸疾関連脊椎関節炎（IBD-SpA）3例，反応性関節炎（ReA）2例，分類不能型脊椎関節炎（uSpA）8例であった．ASAS分類基準は42/57例（73％）で満たしており，残りは臨床症状や画像所見から脊椎関節炎と分類された．患者背景は，性別：男性28例，女性29例（AS：男3女7，PsA：男15女11，PAO：男4女5，IBD-SpA：男2女1，ReA：男2女0，uSpA：男2女6），平均年齢：52.4±13.3歳（23～79歳）であった．HLAは，17例で測定されておりその内6例（35％）でHLA-B27が陽性であった．発症から診断までの期間は中央値でAS：17年，PsA：2.5年，PAO：2年，IBD-SpA：0.9年，ReA：1.1年，uSpA：1.5年であった．治療は，ステロイド：28例（49％），DMARDs：38例（67％），NSAIDs：40例（70％），TNFα阻害剤：18/例（32％）であった．【結論】ASで発症から診断までに長期間要していた．全体としてはHLA-A2陽性の割合が多く，ぶどう膜炎合併の4例はすべてHLA-B27が陽性であった．その他，当科のSpA患者の臨床的特徴を文献的な考察を加えながら検討する．

  The Japan Society for Clinical Immunology, Sep. 2015, Japanese Journal of Clinical Immunology, 38(4) (4), 353 - 353, Japanese


• [Not Available].

  西村 啓佑, 津田 耕作, 明石 健吾, 千藤 荘, 三枝 淳, 森信 暁雄

  【目的】当院通院歴のあるベーチェット病患者を解析し，臨床的特徴や治療実態を把握する．【方法】2008年4月から2014年12月にかけて当科外来通院歴のあるベーチェット病患者を後向きに抽出した．性別，発症年齢，分類，症状，合併症，検査値（HLA），治療薬などを調査した．【結果】ベーチェット病患者は151例で男女比は1:1.1，平均発症年齢は37.0歳であった．分類としては，完全型9.3％，不全型53.6％，特殊型37.1％で腸管型が最も多く，腸管型は血管病変の合併が有意に多かった（P = 0.008）．臨床症状は口腔内潰瘍96.7％，皮膚病変91.4％で，皮膚病変では結節性紅斑様皮疹が47.0％で最多であった．眼症状は52.3％，外陰部潰瘍は55.0％にみられた．腸管病変は回盲部潰瘍が63％と最も多く，血管病変は深部静脈血栓症が60％で最多であった．HLAは71例に検査を行い，HLA-B51, A26陽性はそれぞれ33％，21％であった．薬剤はコルヒチン投与が53.0％と最多で，ステロイド，インフリキシマブ，アダリムマブの投与はそれぞれ29.8％，24.5％，4.0％であった．原疾患による死因は消化管出血，肺胞出血であった．【結論】ベーチェット病に男女差はなく，若年発症が多く過去の報告と同様であった．分類では腸管型と血管型の合併例が多くみられ特徴的であった．

  The Japan Society for Clinical Immunology, Sep. 2015, Japanese Journal of Clinical Immunology, 38(4) (4), 354 - 354, Japanese


• 関節リウマチの病因・病態 血清メタボローム解析による関節リウマチの代謝プロファイルの解明および各種生物学的製剤投与後の代謝変動の解析

  高橋 宗史, 三枝 淳, 岡野 隆一, 千藤 荘, 明石 健吾, 西田 美和, 西村 啓佑, 古形 芳則, 蔭山 豪一, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2015, 日本リウマチ学会総会・学術集会プログラム・抄録集, 59回, 328 - 328, Japanese


• リウマチ性疾患の基礎研究 JAK1/3阻害がMyeloid-derived suppressor cellを誘導し、SKGマウス関節炎を抑制する

  西村 啓佑, 三枝 淳, 明石 健吾, 岡野 隆一, 西田 美和, 高橋 宗史, 千藤 荘, 大西 輝, 古形 芳則, 蔭山 豪一, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2015, 日本リウマチ学会総会・学術集会プログラム・抄録集, 59回, 336 - 336, Japanese


• 感染によりMPO-ANCAが上昇したと考えられた二例

  泉 真祐子, 牟田 愛, 阿部 京介, 梅田 良祐, 一瀬 良英, 千藤 荘, 辻 剛, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2015, 日本リウマチ学会総会・学術集会プログラム・抄録集, 59回, 519 - 519, Japanese


• 原発性シェーグレン患者における睡眠障害の検討

  津田 耕作, 蔭山 豪一, 亀井 優衣子, 仲 郁子, 岡野 隆一, 高橋 宗史, 西田 美和, 明石 健吾, 西村 啓佑, 千藤 荘, 上田 洋, 大西 輝, 古形 芳則, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2015, 日本リウマチ学会総会・学術集会プログラム・抄録集, 59回, 657 - 657, Japanese


• リウマチ性疾患の臨床検査 関節リウマチの活動性把握における血清MMP-3測定の有用性

  上村 裕子, 辻 剛, 一瀬 良英, 梅田 良祐, 千藤 荘, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2015, 日本リウマチ学会総会・学術集会プログラム・抄録集, 59回(12) (12), 384 - 384, Japanese


• MCTD・強皮症 強皮症に合併するボーダーライン肺高血圧症患者におけるスクリーニング検査法の検討

  一瀬 良英, 辻 剛, 阿部 京介, 泉 真祐子, 牟田 愛, 梅田 良祐, 千藤 荘, 上村 裕子, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2015, 日本リウマチ学会総会・学術集会プログラム・抄録集, 59回, 458 - 458, Japanese


• 脊椎関節炎51例の臨床的検討

  千藤荘, 亀井優衣子, 脇大輔, 仲郁子, 津田耕作, 岡野隆一, 明石健吾, 西田美和, 西村啓佑, 高橋宗史, 上田洋, 大西輝, 古形芳則, 蔭山豪一, 三枝淳, 森信暁雄

  2015, 日本リウマチ学会総会・学術集会プログラム・抄録集, 59th


• N-アセチル化転移酵素2(NAT2)遺伝子多型に基づくサラゾスルファピリジン(SASP)の使用法の個別化

  梅田 良祐, 萩原 慶明, 上村 裕子, 一瀬 良英, 千藤 荘, 辻 剛, 熊谷 俊一

  (一社)国際個別化医療学会, Nov. 2014, Personalized Medicine Universe. Japanese Edition, 3(Suppl.2) (Suppl.2), 63 - 63, Japanese


• 当院における炎症性筋疾患(IIM)88例の治療経験

  明石 健吾, 亀井 優衣子, 脇 大輔, 仲 郁子, 津田 耕作, 岡野 隆一, 西田 美和, 西村 啓佑, 高橋 宗史, 上田 洋, 千藤 荘, 杉山 大典, 古形 芳則, 蔭山 豪一, 三枝 淳, 熊谷 俊一, 森信 暁雄

  (一社)日本臨床免疫学会, Aug. 2014, 日本臨床免疫学会会誌, 37(4) (4), 375 - 375, Japanese


• 当院におけるIgG4関連疾患25例の再燃リスクについての検討

  千藤 荘, 亀井 優衣子, 脇 大輔, 仲 郁子, 津田 耕作, 岡野 隆一, 明石 健吾, 西田 美和, 西村 啓佑, 高橋 宗史, 上田 洋, 大西 輝, 古形 芳則, 蔭山 豪一, 三枝 淳, 森信 暁雄

  (一社)日本臨床免疫学会, Aug. 2014, 日本臨床免疫学会会誌, 37(4) (4), 379 - 379, Japanese


• INEFFECTIVE FRACTURE PREVENTION BY BISPHOSPHONATE IN PATIENTS UNDERGOING HIGH DOSE GLUCOCORTICOID THERAPY WITH A FRAX TEN YEAR PROBABILITY GREATER THAN 5.8%

  G. Kageyama, T. Okano, Y. Yamamoto, D. Sugiyama, G. Tsuji, K. Tsuda, S. Takahashi, M. Nishida, K. Akashi, K. Nishimura, S. Sendo, Y. Kogata, J. Saegusa, S. Kawano, S. Kumagai, A. Morinobu

  Jun. 2014, ANNALS OF THE RHEUMATIC DISEASES, 73, 763 - 763, English

  Summary international conference


• SALIVARY METABOLOMICS OF PRIMARY SJOGREN'S SYNDROME

  G. Kageyama, J. Saegusa, S. Tanaka, S. Takahashi, M. Nishida, K. Tsuda, Y. Yamamoto, T. Okano, K. Akashi, K. Nishimura, S. Sendo, Y. Kogata, S. Kawano, A. Morinobu

  Jun. 2014, ANNALS OF THE RHEUMATIC DISEASES, 73, 524 - 525, English

  Summary international conference


• 多発性筋炎・皮膚筋炎 当院における炎症性筋疾患(IIM)88例の治療経験

  明石 健吾, 山本 譲, 津田 耕作, 岡野 隆一, 高橋 宗史, 西田 美和, 西村 啓佑, 千藤 荘, 杉山 大典, 古形 芳則, 蔭山 豪一, 三枝 淳, 熊谷 俊一, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2014, 日本リウマチ学会総会・学術集会プログラム・抄録集, 58回, 437 - 437, Japanese


• 関節リウマチの治療 DMARDs、NSAIDs メトトレキセートの副作用と有効性を予測する薬剤代謝関連酵素の遺伝子多型の網羅的解析

  梅田 良祐, 辻 剛, 一瀬 良英, 千藤 荘, 萩原 慶明, 宇賀 均, 倉田 寛一, 三崎 健太, 中澤 隆, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2014, 日本リウマチ学会総会・学術集会プログラム・抄録集, 58回, 440 - 440, Japanese


• 血清サイトカイン/ケモカインプロファイルは抗CCP抗体陰性関節リウマチ患者の鑑別診断に有用である

  宮本 佳昭, 宇賀 均, 岡澤 貴裕, 三枝 淳, 辻 剛, 千藤 荘, 森信 暁雄, 熊谷 俊一, 倉田 寛一

  (一社)日本リウマチ学会, Mar. 2014, 日本リウマチ学会総会・学術集会プログラム・抄録集, 58回, 505 - 505, Japanese


• 悪性腫瘍合併皮膚筋炎8例の検討

  一瀬 良英, 辻 剛, 阿部 京介, 泉 真祐子, 梅田 良祐, 千藤 荘, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2014, 日本リウマチ学会総会・学術集会プログラム・抄録集, 58回, 551 - 551, Japanese


• 心外膜炎で発症したIgG4関連疾患の一例

  千藤 荘, 山本 譲, 津田 耕作, 岡野 隆一, 明石 健吾, 高橋 宗史, 西田 美和, 西村 啓佑, 古形 芳則, 蔭山 豪一, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2014, 日本リウマチ学会総会・学術集会プログラム・抄録集, 58回, 559 - 559, Japanese


• アレンドロネートとアルファカルシドールを併用しているステロイド服用患者に対するアルファカルシドールからエルデカルシトールへの切り替え効果の検証

  辻 剛, 千藤 荘, 阿部 京介, 泉 真祐子, 梅田 良祐, 一瀬 良英, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2014, 日本リウマチ学会総会・学術集会プログラム・抄録集, 58回, 626 - 626, Japanese


• シェーグレン症候群患者の唾液メタボロミクス

  蔭山 豪一, 三枝 淳, 高橋 宗史, 西田 美和, 山本 譲, 津田 耕作, 岡野 隆一, 明石 健吾, 西村 啓佑, 千藤 荘, 古形 芳則, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2014, 日本リウマチ学会総会・学術集会プログラム・抄録集, 58回, 715 - 715, Japanese


• IgG4関連疾患 当科におけるIgG4関連疾患が疑われた26例の臨床的検討(再燃例について)

  山本 譲, 千藤 荘, 津田 耕作, 岡野 隆一, 明石 健吾, 高橋 宗史, 西田 美和, 西村 啓佑, 古形 芳則, 蔭山 豪一, 三枝 淳, 森信 暁雄

  (一社)日本リウマチ学会, Mar. 2014, 日本リウマチ学会総会・学術集会プログラム・抄録集, 58回, 314 - 314, Japanese


• Personalized medicine in rheumatoid arthritis

  熊谷俊一, 千藤荘, 辻剛

  (一社)国際個別化医療学会, Jan. 2014, Personalized Medicine Universe. Japanese Edition, 2, 10 - 21, Japanese


• Serum Cytokine/Chemokine Profiles Are Useful For Evaluating Pathological Conditions Of Rheumatoid Arthritis and Diagnosing Anti-CCP Antibody-Negative Patients

  Hitoshi Uga, Takahiro Okazawa, Yoshiaki Miyamoto, Takehiro Hasegawa, Jun Saegusa, Goh Tsuji, Sho Sendo, Akio Morinobu, Shunichi Kumagai, Hirokazu Kurata

  Oct. 2013, ARTHRITIS AND RHEUMATISM, 65, S797 - S797, English

  Summary international conference


• Clinical Features Of 127 Patients With Behcet's Disease In Japan

  Keisuke Nishimura, Jun Saegusa, Sho Sendo, Yoshinori Kogata, Goichi Kageyama, Seiji Kawano, Shunichi Kumagai, Akio Morinobu

  Oct. 2013, ARTHRITIS AND RHEUMATISM, 65, S1115 - S1115, English

  Summary international conference


• 関節リウマチにおけるメトトレキセートの副作用予測の為の薬剤代謝関連遺伝子多型の網羅的解析

  上村 裕子, 辻 剛, 千藤 荘, 倉田 寛一, 宇賀 均, 萩原 慶明, 熊谷 俊一

  (一社)日本臨床検査医学会, Sep. 2013, 臨床病理, 61(補冊) (補冊), 211 - 211, Japanese


• 関節リウマチにおけるMMP-3の有用性

  林 秀敏, 高橋 敏夫, 辻 剛, 千藤 荘, 上村 裕子, 熊谷 俊一

  (一社)日本臨床検査医学会, Sep. 2013, 臨床病理, 61(補冊) (補冊), 289 - 289, Japanese


• 膠原病患者のステロイド投与に伴う骨量減少に対するエルデカルシトールとアレンドロネートの併用療法の検討 アルファカルシドールとアレンドロネートの併用療法との比較

  辻 剛, 千藤 荘, 熊谷 俊一

  ステロイド(プレドニゾロン換算平均6.4mg/日)服用中で、アルファカルシドール(ALF)とアレンドロネート(ALN)を併用している膠原病患者25名を対象として、ALFからエルデカルシトール(ELD)への切り替え後24週間の有効性と安全性をレトロスペクティブに検討した。ALFからELDへ切り替えた8例(EA群)とALFを継続した17例(AA群)について、骨密度、骨代謝マーカー、カルシウム代謝マーカー、血清・尿中のCaとクレアチニン、糸球体濾過量を比較した結果、EA群では腰椎骨密度が2.6%増加したのに対してAA群では1.3%低下したが、両群とも副作用や新規骨折の発生はなく、その他の項目にも有意な変化は認めなかった。ALN+ALF併用療法施行中のステロイド投与患者において、ALN+ELD併用療法に切替えた場合の有効性と安全性が確認された。

  ライフサイエンス出版(株), Jun. 2013, Therapeutic Research, 34(6) (6), 819 - 826, Japanese


• 骨粗鬆症と骨代謝 ステロイド性骨粗鬆症に対するエルデカルシトールとアレンドロネートの併用療法の検討 アルファカルシドールとアレンドロネートの併用療法との比較

  辻 剛, 千藤 荘, 一瀬 良英, 梅田 良祐, 阿部 京介, 泉 真祐子, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2013, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 57回・22回, 436 - 436, Japanese


• ホスファチジルセリン依存性抗プロトロンビン抗体陽性の抗リン脂質抗体症候群の2例

  泉 真祐子, 阿部 京介, 梅田 良祐, 一瀬 良英, 千藤 荘, 辻 剛, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2013, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 57回・22回, 519 - 519, Japanese


• 新規発症筋炎患者における筋超音波検査の有用性の検討

  一瀬 良英, 阿部 京介, 泉 真祐子, 梅田 良祐, 岡田 信彦, 千藤 荘, 辻 剛, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2013, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 57回・22回, 523 - 523, Japanese


• 当院における膠原病を合併した肺高血圧症患者の特徴について

  阿部 京介, 泉 真祐子, 梅田 良祐, 一瀬 良英, 千藤 荘, 辻 剛, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2013, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 57回・22回, 529 - 529, Japanese


• 関節リウマチに対するインフリキシマブ10mg/kgを使用した12例の検討

  千藤 荘, 阿部 京介, 泉 真祐子, 梅田 良祐, 一瀬 良英, 辻 剛, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2013, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 57回・22回, 639 - 639, Japanese


• IgG4関連疾患が疑われた16例の臨床的検討

  梅田 良祐, 一瀬 良英, 千藤 荘, 辻 剛, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2013, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 57回・22回, 603 - 603, Japanese


• 血清サイトカイン・プロファイリングによる関節リウマチ(RA)の病態診断

  岡澤 貴裕, 宮本 佳昭, 宇賀 均, 千藤 荘, 辻 剛, 三枝 淳, 森信 暁雄, 熊谷 俊一, 倉田 寛一

  (一社)日本リウマチ学会, Mar. 2013, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 57回・22回, 623 - 623, Japanese


• サラゾスルファピリジン(SASP)単剤治療でde novo B型肝炎を来した関節リウマチ(RA)の1例

  明石健吾, 明石健吾, 仲郁子, 信原由実子, 波内俊三, 中澤隆, 山本譲, 津田耕作, 岡野隆一, 高橋宗史, 西田美和, 西村啓佑, 千藤荘, 古形芳則, 蔭山豪一, 三枝淳, 森信暁雄

  2013, 日本臨床リウマチ学会プログラム・抄録集, 28th


• 遺伝子多型に基づくサラゾスルファピリジン(SASP)の有効性の検討 関節リウマチの個別化医療

  萩原 慶明, 辻 剛, 千藤 荘, 岡田 信彦, 一瀬 良英, 三枝 淳, 熊谷 俊一

  (一社)日本臨床検査医学会, Oct. 2012, 臨床病理, 60(補冊) (補冊), 137 - 137, Japanese


• 特発性炎症性ミオパチーにおける超音波エコー所見の検討

  田井 香織, 松本 真一, 市丸 加奈子, 岡田 信彦, 千藤 荘, 辻 剛, 元木 雅浩, 高松 直子, 熊谷 俊一

  (一社)日本脳神経超音波学会, Jun. 2012, Neurosonology, 25(増刊) (増刊), 77 - 77, Japanese


• 筋疾患における超音波筋エコー所見と病理像の検討

  松本 真一, 田井 香織, 市丸 加奈子, 岡田 信彦, 千藤 荘, 辻 剛, 元木 雅浩, 高松 直子, 熊谷 俊一

  (一社)日本脳神経超音波学会, Jun. 2012, Neurosonology, 25(増刊) (増刊), 77 - 77, Japanese


• 生物学的製剤(TNF阻害薬) 無効 アダリムマブ(ADA)投与RA患者における抗アダリムマブ抗体(AAA)産生と血中ADA濃度および効果の関係(追加報告)

  辻 剛, 河野 誠司, 森信 暁雄, 三枝 淳, 杉山 大典, 八木田 正人, 籏智 さおり, 波内 俊三, 信原 由実子, 中澤 隆, 中村 知子, 岡田 信彦, 千藤 荘, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2012, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 56回・21回, 306 - 306, Japanese


• 免疫抑制療法が有用であったシェーグレン症候群合併肺高血圧症の一例

  一瀬 良英, 梅田 良祐, 山村 愛, 岡田 信彦, 千藤 荘, 辻 剛, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2012, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 56回・21回, 536 - 536, Japanese


• 筋エコーで筋生検部位を特定し皮膚筋炎と診断できた一例

  岡田 信彦, 梅田 良祐, 山村 愛, 一瀬 良英, 千藤 荘, 辻 剛, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2012, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 56回・21回, 607 - 607, Japanese


• SLE様症状を呈したパルボウイルス感染症の3例に関する検討

  梅田 良祐, 山村 愛, 千藤 荘, 一瀬 良英, 岡田 信彦, 辻 剛, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2012, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 56回・21回, 546 - 546, Japanese


• 関節リウマチの治療 DMARDs・NSAIDs(3) 遺伝子多型に基づくサラゾスルファピリジン(SASP)の有効的使用法 関節リウマチの個別化医療

  熊谷 俊一, 萩原 慶明, 千藤 荘, 岡田 信彦, 杉山 大典, 三枝 淳, 辻 剛

  (一社)日本リウマチ学会, Mar. 2012, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 56回・21回, 445 - 445, Japanese


• ANCA関連血管炎に対するステロイド早期減量法についての検討

  千藤 荘, 梅田 良祐, 山村 愛, 一瀬 良英, 岡田 信彦, 辻 剛, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2012, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 56回・21回, 538 - 538, Japanese


• NAT2遺伝子多型に基づくサラゾスルファピリジンの効果と副作用の検討 リウマチ患者の個別化医療に向けて

  萩原 慶明, 辻 剛, 千藤 荘, 岡田 信彦, 三枝 淳, 杉山 大典, 熊谷 俊一

  (一社)日本臨床検査医学会, Oct. 2011, 臨床病理, 59(補冊) (補冊), 277 - 277, Japanese


• The differential diagnosis of IgG4 related disease

  辻 剛, 千藤 荘, 熊谷 俊一

  (株)医学書院, Aug. 2011, 臨床検査, 55(8) (8), 793 - 798, Japanese


• アダリムマブ アダリムマブ投与RA患者での抗アダリムマブ抗体と治療効果の関係(多施設共同研究)

  辻 剛, 河野 誠司, 森信 暁雄, 三枝 淳, 杉山 大典, 八木田 正人, 籏智 さおり, 波内 俊三, 信原 由実子, 中澤 隆, 西村 啓佑, 中村 知子, 千藤 荘, 熊谷 俊一

  (一社)日本リウマチ学会, Jun. 2011, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 55回・20回, 300 - 300, Japanese


• SLE 膠原病難治病態に対するAbsorption Profileに基づくシクロスポリン(CsA)の積極的投与

  林 宏樹, 千藤 荘, 杉山 大典, 笠木 伸平, 辻 剛, 三枝 淳, 西村 邦宏, 河野 誠司, 森信 暁雄, 熊谷 俊一, 湯沢 由紀夫

  (一社)日本リウマチ学会, Jun. 2011, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 55回・20回, 444 - 444, Japanese


• 滑膜炎を呈したクリオグロブリン血症の一例

  千藤 荘, 辻 剛, 熊谷 俊一

  (一社)日本リウマチ学会, Jun. 2011, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 55回・20回, 590 - 590, Japanese


• ループス腎炎に対するミゾリビンとタクロリムス併用による臨床効果と薬物血中濃度

  辻剛, 千藤荘, 熊谷俊一, 林宏樹

  2011, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 55th-20th


• 膠原病難治病態に対するAbsorption Profileに基づくシクロスポリンの積極的投与

  林 宏樹, 千藤 荘, 杉山 大典, 辻 剛, 志田 有里, 大松 秀明, 平野 剛, 平井 みどり, 熊谷 俊一

  (一社)日本TDM学会, Jun. 2010, TDM研究, 27(3) (3), s225 - s225, Japanese


• CNSループス 2009年当施設で経験したSLEに合併する無菌性髄膜炎の6例

  辻 剛, 千藤 荘, 三浦 菜津子, 笠木 伸平, 林 宏樹, 三枝 淳, 杉本 健, 河野 誠司, 森信 暁雄, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2010, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 54回・19回, 481 - 481, Japanese


• 経過中に無γグロブリン症を合併しSLEは改善したがRAは進行した重複症候群の1例

  三浦 菜津子, 三枝 淳, 笠木 伸平, 河野 誠司, 千藤 荘, 森信 暁雄, 辻 剛, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2010, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 54回・19回, 611 - 611, Japanese


• ベーチェット病に大動脈炎と側頭動脈炎を合併した一例

  笠木 伸平, 千藤 荘, 三浦 菜津子, 林 宏樹, 三枝 淳, 辻 剛, 杉本 健, 河野 誠司, 森信 暁雄, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2010, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 54回・19回, 678 - 678, Japanese


• 広範な硬膜外腫瘤による圧迫性脊髄症と腹部大動脈周囲炎を呈したANCA関連血管炎の一例

  千藤 荘, 笠木 伸平, 辻 剛, 三浦 菜津子, 林 宏樹, 三枝 淳, 杉本 健, 河野 誠司, 森信 暁雄, 熊谷 俊一

  (一社)日本リウマチ学会, Mar. 2010, 日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集, 54回・19回, 710 - 710, Japanese


• 維持透析患者における負荷心筋シンチの有用性

  坂口 輝洋, 北川 章充, 浅野 実奈子, 神村 豊, 千藤 荘, 濱口 京子, 長屋 啓, 立松 美穂, 鈴木 祥代, 倉田 圭, 稲熊 大城

  (一社)日本透析医学会, May 2009, 日本透析医学会雑誌, 42(Suppl.1) (Suppl.1), 586 - 586, Japanese


• 腹膜透析症例に対するシナカルセト塩酸塩の効果

  浅野 実奈子, 北川 章充, 神村 豊, 千藤 荘, 濱口 京子, 長屋 啓, 立松 美穂, 鈴木 祥代, 倉田 圭, 稲熊 大城

  (一社)日本透析医学会, May 2009, 日本透析医学会雑誌, 42(Suppl.1) (Suppl.1), 650 - 650, Japanese


• 腹膜透析離脱しえた2例

  北川 章充, 浅野 実奈子, 神村 豊, 千藤 荘, 濱口 京子, 長屋 啓, 立松 美穂, 鈴木 祥代, 倉田 圭, 稲熊 大城

  (一社)日本透析医学会, May 2009, 日本透析医学会雑誌, 42(Suppl.1) (Suppl.1), 681 - 681, Japanese


• 重症心不全を合併し左室縮小形成術を施行した血液透析患者の一例

  濱口 京子, 北川 章充, 浅野 実奈子, 神村 豊, 千藤 荘, 長屋 啓, 立松 美穂, 鈴木 祥代, 倉田 圭, 稲熊 大城

  (一社)日本透析医学会, May 2009, 日本透析医学会雑誌, 42(Suppl.1) (Suppl.1), 827 - 827, Japanese


• 経皮経管的腎動脈血管形成術(PTRA)により透析離脱できた1例

  長屋 啓, 北川 章充, 浅野 実奈子, 神村 豊, 千藤 荘, 濱口 京子, 立松 美穂, 鈴木 祥代, 倉田 圭, 稲熊 大城

  (一社)日本透析医学会, May 2009, 日本透析医学会雑誌, 42(Suppl.1) (Suppl.1), 684 - 684, Japanese


• 排液不良を繰り返した腹膜透析患者の1例

  神村 豊, 北川 章充, 浅野 実奈子, 千藤 荘, 濱口 京子, 長屋 啓, 立松 美穂, 鈴木 祥代, 倉田 圭, 稲熊 大城

  (一社)日本透析医学会, May 2009, 日本透析医学会雑誌, 42(Suppl.1) (Suppl.1), 639 - 639, Japanese


• 保存期慢性腎臓病において摂取ビタミンDが不足している

  立松 美穂, 北川 章充, 浅野 実奈子, 神村 豊, 千藤 荘, 濱口 京子, 長屋 啓, 鈴木 祥代, 倉田 圭, 稲熊 大城

  (一社)日本腎臓学会, Apr. 2009, 日本腎臓学会誌, 51(3) (3), 316 - 316, Japanese


• 心血管病(CVD)発症におけるビタミンDの役割

  稲熊 大城, 北川 章充, 浅野 実奈子, 神村 豊, 千藤 荘, 濱口 京子, 長屋 啓, 立松 美穂, 鈴木 祥代, 倉田 圭

  (一社)日本腎臓学会, Apr. 2009, 日本腎臓学会誌, 51(3) (3), 237 - 237, Japanese


• 保存期慢性腎臓病においてビタミンD補充が導入期血中ビタミンDレベルに与える影響

  稲熊 大城, 浅野 実奈子, 神村 豊, 千藤 荘, 濱口 京子, 長屋 啓, 立松 美穂, 鈴木 祥代, 倉田 圭

  (株)日本メディカルセンター, Oct. 2008, 腎と骨代謝, 21(4) (4), 349 - 349, Japanese


• 高度貧血を認めたNutcracker現象の一例

  北川 章充, 浅野 実奈子, 神村 豊, 千藤 荘, 濱口 京子, 長屋 啓, 立松 美穂, 鈴木 祥代, 倉田 圭, 稲熊 大城

  (一社)日本腎臓学会, Aug. 2008, 日本腎臓学会誌, 50(6) (6), 679 - 679, Japanese


• 重症筋無力症に合併したネフローゼ症候群の一例

  倉田 圭, 北川 章充, 浅野 実奈子, 神村 豊, 千藤 荘, 濱口 京子, 長屋 啓, 立松 美穂, 鈴木 祥代, 稲熊 大城

  (一社)日本腎臓学会, Aug. 2008, 日本腎臓学会誌, 50(6) (6), 693 - 693, Japanese


• 木村病に合併したネフローゼ症候群の一例

  神村 豊, 浅野 実奈子, 千藤 荘, 濱口 京子, 長屋 啓, 立松 美穂, 鈴木 祥代, 倉田 圭, 稲熊 大城

  (一社)日本腎臓学会, Aug. 2008, 日本腎臓学会誌, 50(6) (6), 708 - 708, Japanese


• 深部静脈血栓症をきたした多発性嚢胞腎の一例

  濱口 京子, 稲熊 大城, 倉田 圭, 鈴木 祥代, 立松 美穂, 長屋 啓, 浅野 実奈子, 神村 豊, 千藤 荘, 北川 章充

  (一社)日本腎臓学会, Aug. 2008, 日本腎臓学会誌, 50(6) (6), 711 - 711, Japanese


• 尿たんぱくのコントロールに難渋したループス腎炎の1例

  長屋 啓, 北川 章充, 浅野 実奈子, 神村 豊, 千藤 荘, 濱口 京子, 立松 美穂, 鈴木 祥代, 倉田 圭, 稲熊 大城

  (一社)日本腎臓学会, Aug. 2008, 日本腎臓学会誌, 50(6) (6), 709 - 709, Japanese


• 炎症性腸疾患と腎障害との合併を認めた一例

  千藤 荘, 北川 章充, 浅野 実奈子, 神村 豊, 濱口 京子, 長屋 啓, 立松 美穂, 鈴木 祥代, 倉田 圭, 稲熊 大城

  (一社)日本腎臓学会, Aug. 2008, 日本腎臓学会誌, 50(6) (6), 696 - 696, Japanese


• 高齢者MPO-ANCA関連血管炎の再燃にミゾリビン(MZR)が有効であった一例

  浅野 実奈子, 北川 章充, 神村 豊, 千藤 荘, 濱口 京子, 長屋 啓, 立松 美穂, 鈴木 祥代, 倉田 圭, 稲熊 大城

  (一社)日本腎臓学会, Aug. 2008, 日本腎臓学会誌, 50(6) (6), 707 - 707, Japanese


• 多くのCKD紹介患者には、RAS抑制薬がすでに使われている

  稲熊 大城, 浅野 実奈子, 神村 豊, 千藤 荘, 長屋 啓, 原 和弘, 立松 美穂, 鈴木 祥代, 倉田 圭

  (一社)日本腎臓学会, Apr. 2008, 日本腎臓学会誌, 50(3) (3), 259 - 259, Japanese


• CKD病診連携パスの使用経験

  稲熊 大城, 浅野 実奈子, 神村 豊, 千藤 荘, 長屋 啓, 原 和弘, 立松 美穂, 鈴木 祥代, 倉田 圭

  (一社)日本腎臓学会, Apr. 2008, 日本腎臓学会誌, 50(3) (3), 351 - 351, Japanese


• ANCA関連腎炎は透析導入後も予後は悪い

  千藤荘, 長屋啓, 原和弘, 立松美穂, 鈴木祥代, 倉田圭, 稲熊大城

  2008, 日本透析医学会雑誌, 41(Supplement 1) (Supplement 1)


• 50分間のVf蘇生後低体温療法にて完全社会復帰した症例のICU管理

  千藤 荘, 市原 利彦, 長谷川 隆一, 川瀬 正樹, 中島 義仁, 上田 裕一

  (一社)日本集中治療医学会, Jan. 2008, 日本集中治療医学会雑誌, 15(Suppl.) (Suppl.), 198 - 198, Japanese


• 二次救急病院の果たすべき役割と病々・病診連携 二次救急医療施設における現状と病診連携、病々連携の現状と将来

  市原 利彦, 中村 仁美, 木村 紀久, 千藤 荘, 久保田 陽介

  (一社)日本臨床救急医学会, Apr. 2007, 日本臨床救急医学会雑誌, 10(2) (2), 166 - 166, Japanese


• 救急医療におけるチーム医療のあり方 救急医療におけるチーム医療のあり方 各職種間の目指すべき接点

  木村 紀久, 市原 利彦, 中村 仁美, 千藤 荘, 久保田 陽介

  (一社)日本臨床救急医学会, Apr. 2007, 日本臨床救急医学会雑誌, 10(2) (2), 184 - 184, Japanese


• 超高齢者(90歳以上)救急の検討 二次救急医療施設の病診連携における問題点と課題

  高橋 光太, 市原 利彦, 中村 仁美, 千藤 荘, 久保田 陽介, 木村 紀久

  (一社)日本臨床救急医学会, Apr. 2007, 日本臨床救急医学会雑誌, 10(2) (2), 202 - 202, Japanese


• 当院におけるドクターカーの現状

  浅井 裕充, 市原 利彦, 木村 紀久, 千藤 荘, 久保田 陽介, 中村 仁美

  (一社)日本臨床救急医学会, Apr. 2007, 日本臨床救急医学会雑誌, 10(2) (2), 221 - 221, Japanese


• 当院における院内AED症例の検討

  千藤 荘, 市原 利彦, 木村 紀久, 中村 仁美, 久保田 陽介

  (一社)日本臨床救急医学会, Apr. 2007, 日本臨床救急医学会雑誌, 10(2) (2), 245 - 245, Japanese


• 皮下気腫の進行で3度の胸腔ドレナージを要した多発外傷の1例

  久保田陽介, 市原利彦, 中村仁美, 千藤荘, 木村紀久

  2007, 日本臨床救急医学会雑誌, 10(2) (2)

• 胸膜炎を呈した強皮症の1例

  山本 真子, 山下 真依, 片山 素子, 能勢 洋子, 上田 洋, OKANO TAKAICHI, SENDOU SHOU, AKASHI KENGO, SAEGUSA JUN, MORINOBU AKIO

  内科学会 第223回近畿地方会, Mar. 2019, Japanese, 京都, Domestic conference

  Oral presentation


• NPSLEとTMAの合併に対して、ステロイドパルス、血漿交換、シクロホスファミドパルスを併用し早期に改善しえた1例

  安積 陽也, 山下 真依, OKANO TAKAICHI, AKASHI KENGO, 片山 素子, 能瀬 洋子, 上田 洋, SENDOU SHOU, SAEGUSA JUN, MORINOBU AKIO

  内科学会 第223回近畿地方会, Mar. 2019, Japanese, 京都, Domestic conference

  Oral presentation


• 顔面から頸部の表在感覚障害をきたしたIgA血管炎の1例

  寺田 菜々子, SENDOU SHOU, 片山 素子, 能瀬 洋子, 山下 真依, OKANO TAKAICHI, 上田 洋, AKASHI KENGO, SAEGUSA JUN, MORINOBU AKIO

  第222回日本内科学会近畿地方会, Dec. 2018, Japanese, 大阪, Domestic conference

  Oral presentation


• サイトメガロウイルス食道炎・胃炎による門脈ガス血症を来した多発血管炎性肉芽腫症

  森 直樹, SENDOU SHOU, 片山 素子, 能瀬 洋子, 山下 真依, OKANO TAKAICHI, 上田 洋, AKASHI KENGO, SAEGUSA JUN, MORINOBU AKIO

  第222回日本内科学会近畿地方会, Dec. 2018, Japanese, 大阪, Domestic conference

  Oral presentation


• Tofacitinib Facilitates the Expansion of Myeloid-Derived Suppressor Cells and Ameliorates Interstitial Lund Disease in SKG Mice.

  Sho Sendo, Jun Saegusa, Hirotaka Yamada, Akio Morinobu

  第47回日本免疫学会総会・学術集会, Dec. 2018, English, 福岡, Domestic conference

  Oral presentation


• 顔面から頸部の表在感覚障害をきたしたIgA血管炎の1例

  SENDOU SHOU, SAEGUSA JUN, 上田 洋, OKANO TAKAICHI, AKASHI KENGO, MORINOBU AKIO

  第46回 日本臨床免疫学会総会, Nov. 2018, Japanese, 長野, Domestic conference

  Public symposium


• トファシチニブは骨髄由来抑制性細胞(MDSC)の増殖を促しSKGマウスの間質性肺炎を抑制する

  SENDOU SHOU, SAEGUSA JUN, 山田 啓貴, 上田 洋, MORINOBU AKIO

  第46回 日本臨床免疫学会総会, Nov. 2018, Japanese, 長野, Domestic conference

  Oral presentation


• サイトメガロウイルス食道炎・胃炎による門脈ガス血症を来した多発血管炎性肉芽腫症

  森 直樹, SENDOU SHOU, 片山 素子, 寺田 菜々子, 能瀬 洋子, 山下 真依, OKANO TAKAICHI, 上田 洋, AKASHI KENGO, OONISHI AKIRA, SAEGUSA JUN, MORINOBU AKIO

  第46回 日本臨床免疫学会総会, Nov. 2018, Japanese, 長野, Domestic conference

  Poster presentation


• Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice.

  Sendo S, Saegusa J, Ichise Y, Yamada H, Naka I, Ueda Y, Okano T, Morinobu A

  American College of Rheumatology 82nd Annual Scientific Meeting., Nov. 2018, English, シカゴ, International conference

  Poster presentation


• Subjective well-being among rheumatoid arthritis patients.

  Kageyama G, Onishi A, Ueda Y, Akashi Kengo, Sendo S, Saegusa J, Morinobu A

  American College of Rheumatology 82nd Annual Scientific Meeting., Nov. 2018, English, シカゴ, International conference

  Poster presentation


• Combined inhibition of mechanistic target of rapamycin and glutamine metabolism inhibits CD4 T cell proliferation and Th17 differentiation, facilitates the expansion of myeloid-derived suppressor cells, and synergistically ameliorates arthritis in SKG mic

  Ueda Y, Saegusa J, Okano T, Sendo S, Yamada H, Yamada H, Onishi A, Morinobu A

  American College of Rheumatology 82nd Annual Scientific Meeting., Nov. 2018, English, シカゴ, International conference

  Poster presentation


• The effects of trimethoprim-sulfamethoxazole on disease activity in patients with rheumatoid arthritis.

  Onishi A, Akashi K, Hashimoto M, Yamamoto W, Murata K, Katayama M, Amuro H, Son Y, Yoshida S, Nagai K, Hara R, Ebina K, Hirano T, Yamamoto Y, Yamada H, Ichise Y, Naka I, Okano T, Takahashi S, Ueda Y, Sendo S, Saegusa J, Morinobu A

  Annual European Congress of Rheumatology, Jun. 2018, English, アムステルダム, International conference

  Poster presentation


• Rapid elevation of erythrocyte methotrexate-polyglutamate3 (MTX-PG3) levels related to the efficacy of MTX in patients with rheumatoid arthritis (RA).

  Nishida M, Tsuji G, Takahashi M, Saitou T, Noda Y, Yoneda K, Amano N, Sendo S, Onishi A, Morinobu A, Shinohara M, Kumagai S

  Annual European Congress of Rheumatology, Jun. 2018, English, アムステルダム, International conference

  Poster presentation


• Differences in clinical courses and serum markers of interstitial lung disease associated with anti-aminoacyl-transfer rna synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody-positive polymyositis/dermatomyositis.

  Akashi K, Nose Y, Shirai T, Fujikawa Y, Nagamoto T, Okano T, Takahashi S, Sendo S, Onishi A, Saegusa J, Morinobu A

  Annual European Congress of Rheumatology, Jun. 2018, English, アムステルダム, International conference

  Poster presentation


• 大型血管炎症例集積研究 高安動脈炎における当院での治療成績とトシリズマブの有効性についての検討

  藤川 良一, SENDOU SHOU, 大木 洋子, 白井 太一朗, 永本 匠, 山本 譲, 山田 啓貴, 一瀬 良英, 仲 郁子, 岡野 隆一, 髙橋 宗史, 上田 洋, AKASHI KENGO, OONISHI AKIRA, SAEGUSA JUN, MORINOBU AKIO

  第62回日本リウマチ学会総会・学術集会プログラム, Apr. 2018, Japanese, 東京, Domestic conference

  Oral presentation


• 仙腸関節炎に対してTNFα阻害薬で加療中に消化管穿孔で顕在化した腸管型ベーチェット病の一例

  大木 洋子, SENDOU SHOU, 白井 太一朗, 藤川 良一, 永本 匠, OKANO TAKAICHI, 髙橋 宗史, AKASHI KENGO, OONISHI AKIRA, SAEGUSA JUN, MORINOBU AKIO

  第62回日本リウマチ学会総会・学術集会プログラム, Apr. 2018, Japanese, 東京, Domestic conference

  Poster presentation


• 関節リウマチ治療におけるニューモシスティス肺炎予防の実態

  AKASHI KENGO, OONISHI AKIRA, 永井 孝治, 吉田 周造, 山本 渉, 橋本 求, 村田 浩一, 孫 瑛洙, 安室 秀樹, 原 良太, 平野 亨, 蛯名 耕介, 片山 昌紀, SENDOU SHOU, SAEGUSA JUN, MORINOBU AKIO

  第62回日本リウマチ学会総会・学術集会プログラム, Apr. 2018, Japanese, 東京, Domestic conference

  Poster presentation


• Tofacitinib Facilitate the Expansion of MDSCs and Suppress the Progression of Interstitial Lung Disease in SKG Mice.

  Shou Sendou, Jun Saegusa, You Ueda, Ikuko Naka, Yoshihide Ichise, Hirotaka Yamada, Yuzuru Yamamoto, Akio Morinobu

  第62回日本リウマチ学会総会・学術集会プログラム, Apr. 2018, English, 東京, Domestic conference

  Oral presentation


• Inhibition of mTOR pathway and glutaminolysis facilitates the expansion of myeloidderived suppressor cells and synergistically ameliorates arthritis in SKG mice

  Ueda Y, Saegusa J, Okano T, Sendo S, Yamada H, Ichise Y, Naka I, Takahashi S, Akashi K, Onishi A, Morinobu A

  第62回日本リウマチ学会総会・学術集会プログラム, Apr. 2018, English, 東京, Domestic conference

  Oral presentation


• Combined inhibition of mTOR and glutamine metabolism inhibits CD4+ T cell proliferation and Th17 differentiation, facilitates the expansion of myeloid-derived suppressor cells, and synergistically ameliorates arthritis in SKG mice.

  Ueda Y, Saegusa J, Okano T, Sendo S, Yamada H, Ichise Y, Naka I, Takahashi S, Akashi K, Onishi A, Morinobu A

  第62回日本リウマチ学会総会・学術集会プログラム, Apr. 2018, English, 東京, Domestic conference

  Public symposium


• SKGマウスの間質性肺炎ではユニークな免疫寛容性樹状細胞が誘導される

  Saegusa Jun, Morinobu Akio

  第4回JCRベーシックリサーチカンファレンス, Oct. 2017, Japanese, 日本リウマチ学会, 東京, Domestic conference

  Oral presentation


• 炎症性筋疾患に合併する間質性肺疾患における血清マーカーの推移

  Akashi Kengo, 大木 洋子, 白井 太一朗, 藤川 良一, 永本 匠, 山本 譲, 山田 啓貴, 一瀬 良英, 仲 郁子, 高橋 宗史, 上田 洋, Onishi Akira, Saegusa Jun, Morinobu Akio

  第45回日本臨床免疫学会総会, Sep. 2017, Japanese, 日本臨床免疫学会, 東京, Domestic conference

  Poster presentation


• シェーグレン症候群による亜急性感覚失調性ﾆｭｰﾛﾊﾟﾁｰの1例

  Akashi Kengo, 白井 太一朗, 大木 洋子, 永本 匠, 藤川 良一, 髙橋 宗史, Onishi Akira, Saegusa Jun, Morinobu Akio

  第45回日本臨床免疫学会総会, Sep. 2017, Japanese, 日本臨床免疫学会, 東京, Domestic conference

  Poster presentation


• Tacrolimusで初めて治療し得た心筋障害合併症を含むTAFRO症候群の2症例

  白井 太一朗, 脇 大輔, Akashi Kengo, Onishi Akira, Saegusa Jun, Morinobu Akio

  第45回日本臨床免疫学会総会, Sep. 2017, Japanese, 日本臨床免疫学会, 東京, Domestic conference

  Poster presentation


• SKGマウスの間質性肺炎ではユニークな免疫寛容性樹状細胞が誘導される

  Saegusa Jun, 髙橋 宗史, Morinobu Akio

  第38回日本炎症・再生医学会, Jul. 2017, Japanese, 日本炎症・再生医学会, 大阪, Domestic conference

  Poster presentation


• Methotrexate Polyglutamates Levels in Erythrocytes Were Genetically Affected in RA Patients with Low Disease Activity for Long Period.

  Kumagai S, Nishida M, Uemura Y, Izumi M, Abe K, Yoneda K, Noda Y, Onishi Akira, Shinohara Masakazu, Tsuji G

  EULAR Congress 2017Annual European Congress of Rheumatology, Jun. 2017, English, European League Against Rheumatism, マドリッド, スペイン, International conference

  Poster presentation


• Longitudinal Study of The Effects of Disease Activity on Renal Function In Patients With Rheumatoid Arthritis Utilizing Linear Mixed Effect models - ANSWER Cohort Study -

  Onishi Akira, Akashi Kengo, Hashimoto M, Furu M, Yamamoto W, Katayama M, Hara R, Fujimura T, Yoshida S, Nagai K, Hirano T, Ebina K, Son Y, Amuro H, Yamada Hideto, Ichise Y, Waki D, Naka I, Tsuda K, Okano T, Takahashi Satoru, Ueda Y, Kogata Y, Saegusa Jun, Morinobu Akio

  EULAR Congress 2017Annual European Congress of Rheumatology, Jun. 2017, English, European League Against Rheumatism, マドリッド, スペイン, International conference

  Oral presentation


• 致死的経過を辿ったRheumatoid Vasculitis に伴う肺動脈性高血圧症の一例

  市川 晋也, Akashi Kengo, 白井 太一朗, 山本 譲, 脇 大輔, Onishi Akira, 古形 芳則, Saegusa Jun, Morinobu Akio

  第61回日本リウマチ学会総会・学術集会, Apr. 2017, Japanese, 日本リウマチ学会, 福岡, Domestic conference

  Poster presentation


• 骨粗鬆症と骨代謝／変形性関節症・軟骨ステロイド骨粗鬆症(GIO)に対するデノスマブの有効性 2年間の使用成績

  Akashi Kengo, 西村 啓佑, 蔭山 豪一, 市川 晋也, 白井 太一朗, 山本 譲, 一瀬 良英, 山田 啓貴, 仲 郁子, 津田 耕作, 脇 大輔, 髙橋 宗史, 上田 洋, Onishi Akira, 古形 芳則, Saegusa Jun, Morinobu Akio

  第61回日本リウマチ学会総会・学術集会, Apr. 2017, Japanese, 日本リウマチ学会, 福岡, Domestic conference

  Public symposium


• シクロスポリンが奏功した自己免疫性好中球減少症を伴う乾癬性関節炎の一例

  白井 太一朗, 脇 大輔, 市川 晋也, 山本 譲, Akashi Kengo, Onishi Akira, 古形 芳則, Saegusa Jun, Morinobu Akio

  第61回日本リウマチ学会総会・学術集会, Apr. 2017, Japanese, 日本リウマチ学会, 福岡, Domestic conference

  Poster presentation

• The Japanese Association for Infectious Diseases

  Jun. 2025 - Present


• Japanese Association For Protein Phosphatase Research (JAPPR)

  Jan. 2025 - Present


• Japanese Society for Sjogren's Syndrome

  Sep. 2024 - Present


• Japanese Society of Laboratory Medicine

  Jan. 2022 - Present


• The Japanese Society of Inflammation and Regeneration

  Mar. 2017 - Present


• Japan Society for Immunology

  Dec. 2014 - Present


• Japan Spondyloarthritis Society

  Oct. 2014 - Present


• Japan Society for Clinical Immunology

  Aug. 2014 - Present


• Japan College of Rheumatology

  Mar. 2009 - Present


• The Japanese Society of Internal Medicine

  Apr. 2007 - Present

• Regulation of neddylation system as a novel therapeutic target of rheumatoid arthritis and rheumatoid lung

  千藤 荘

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Early-Career Scientists, Kobe University, 01 Apr. 2023 - 31 Mar. 2026

  2023年度の研究計画として、①SKGマウスの関節炎においてNeddylation経路に異常がみられるかの解明、②SKG-ILDにおいてNeddylation経路に異常がみられるかの解明、③Neddylation阻害剤が免疫細胞の活性化を抑えるかの解明（in vitro）の3点を挙げていた。①②に関しては、Naive SKGマウス（コントロール）と関節炎および間質性肺炎を誘導したマウスを作成し各組織（関節、肺）を摘出し凍結保存した。今後、これらの保存検体を用いてNeddylationに関わる遺伝子をqPCRで解析していく予定である。③に関しては、Naive SKGマウスから骨髄細胞を単離し、in vitroにおいてNeddylation阻害剤存在下で樹状細胞分化を行ったところ、コントロール（DMSO）との比較しNeddylation阻害剤は樹状細胞上のPD-L1の発現を増加させた。一方、MDSCは増加させなかった。現在、樹状細胞とT細胞との共培養実験を行っており、Neddylation阻害剤を作用させた樹状細胞が免疫寛容性を持つのか検討中である。


• Development of Novel Therapeutic Strategies for Rheumatoid Arthritis and Rheumatoid Lung Disease through Regulation of Neddylation

  Sho Sendo

  公益財団法人ひょうご科学技術協会, 令和5年度学術研究助成, Kobe University Hospital, Apr. 2023 - Mar. 2024


• Characterization of the organ-specific subsets of MDSCs and its application to novel treatment using arthritis model mice

  千藤 荘

  Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research, Grant-in-Aid for Early-Career Scientists, Kobe University, Apr. 2018 - Mar. 2021, Principal investigator

  2023年度の研究計画としては、①SKGマウスの各組織由来MDSCの表現型・機能に差異があるか（組織特異的MDSCサブセット）の解明に加え、②肺由来MDSCの特異性の有無についての探索、③MDSCの増殖や機能に影響を与える薬剤の探索を挙げていた。①については、関節由来MDSCが破骨細胞分化能を持ち、in vitro、in vivo共に骨破壊に関与していることを証明し学術誌に掲載された（Front Immunol. 2024; 15: 1168323.）。②については、マイクロアレイの結果から間質性肺炎モデルマウスの肺由来MDSCは骨髄や脾臓由来MDSCと比較しある種のケモカイン発現が高いことが判明し、それらに対応するケモカインレセプターの発現が肺内のCD8陽性T細胞、樹状細胞、マクロファージで高いことを見出した。現在、そのレセプターを阻害する薬剤を用いて、間質性肺炎に対する効果を確認中である。③については、現在関節リウマチに用いられている5種類のJAK阻害剤間でMDSCの増殖や機能に与える影響が異なるか解析中である。また、in vitroでタンパク質翻訳後修飾を制御する薬剤が、MDSCへの分化ではなく、他の抑制性骨髄球系細胞への分化を促す可能性があることを見つけている。

  Competitive research funding


• Roles for myeloid derived suppressor cells in rheumatic diseases

  Sho Sendo

  GlaxoSmithKline, GlaxoSmithKline Research Grant 2017, Kobe University Hospital, Apr. 2017 - Mar. 2018, Principal investigator